{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":1742,"total_is_capped":false,"direct_labels_cover":5,"predictions_cover":1742,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"dd57b2333e5f","filters":{"topic":"Chronic Lymphocytic Leukemia Research"}},"results":[{"id":"W2120319857","doi":"10.1056/nejmoa1313984","title":"Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1500,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"","keywords":"Chlorambucil; Obinutuzumab; Medicine; Rituximab; Internal medicine; Hazard ratio; Gastroenterology; Chronic lymphocytic leukemia; Oncology; Chemotherapy; Confidence interval; Leukemia; Cyclophosphamide; Lymphoma","authors":[{"name":"Valentin Goede","is_ca":false},{"name":"Kirsten Fischer","is_ca":false},{"name":"Raymonde Busch","is_ca":false},{"name":"Anja Engelke","is_ca":false},{"name":"Barbara Eichhorst","is_ca":false},{"name":"Clemens‐Martin Wendtner","is_ca":false},{"name":"Tatiana Chagorova","is_ca":false},{"name":"Javier de la Serna","is_ca":false},{"name":"Marie‐Sarah Dilhuydy","is_ca":false},{"name":"Thomas Illmer","is_ca":false},{"name":"Stephen Opat","is_ca":false},{"name":"Carolyn Owen","is_ca":true},{"name":"Olga Samoylova","is_ca":false},{"name":"Karl‐Anton Kreuzer","is_ca":false},{"name":"Stephan Stilgenbauer","is_ca":false},{"name":"Hartmut Döhner","is_ca":false},{"name":"Anton W. Langerak","is_ca":false},{"name":"Matthias Ritgen","is_ca":false},{"name":"Michael Kneba","is_ca":false},{"name":"Elina Asikanius","is_ca":false},{"name":"Kathryn Humphrey","is_ca":false},{"name":"Michael Wenger","is_ca":false},{"name":"Michael Hallek","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01466347416376183,"gpt":0.2802251531773841,"spread":0.2655616790136222,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007900941,0.0002374285,0.0007311284,0.0002667318,0.0004438497,0.0003596105,0.0001836543,0.0004557091,0.001119407],"category_scores_gemma":[0.001708327,0.0001502788,0.0004823856,0.0003869059,0.0003282014,0.0002178317,0.00029932,0.0004434786,0.00009920474],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005589147,"about_ca_system_score_gemma":0.0007315595,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000746233,"about_ca_topic_score_gemma":0.001745986,"domain_scores_codex":[0.9995086,0.0002503065,0.00004546728,0.00006182212,0.00005056266,0.00008317053],"domain_scores_gemma":[0.9989685,0.0004165543,0.0002699072,0.00002573183,0.00002219598,0.0002972371],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1999718,0.002775164,0.6789398,0.0007309334,0.0009191,0.001916037,0.0003613135,0.002779977,0.007767097,0.0002947788,0.001080438,0.1024636],"study_design_scores_gemma":[0.04385455,0.1331854,0.7955765,0.0003971597,0.002191874,0.008343086,0.0005450701,0.004990914,0.00278154,0.0008385946,0.007226755,0.00006867231],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973844,0.002065411,0.00004154398,0.00008954146,0.00001477198,0.00003555543,0.00003859256,0.000002297952,0.0003278656],"genre_scores_gemma":[0.9992269,0.0004081781,0.00009343674,0.00009075705,0.00003632105,0.00003463479,0.00006835241,5.038376e-7,0.00004084566],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001119407,"threshold_uncertainty_score":0.004178464,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2326175431","doi":"10.1056/nejm200012143432402","title":"Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia","year":2000,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1004,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; McGill University","keywords":"Chlorambucil; Fludarabine; Chronic lymphocytic leukemia; Medicine; Internal medicine; Gastroenterology; Chemotherapy; Surgery; Leukemia; Cyclophosphamide","authors":[{"name":"Bercedis L. Peterson","is_ca":false},{"name":"Frederick R. Appelbaum","is_ca":false},{"name":"Jonathan E. Kolitz","is_ca":false},{"name":"Laurence Elias","is_ca":false},{"name":"Lois E. Shepherd","is_ca":true},{"name":"John Hines","is_ca":false},{"name":"Gregory A. Threatte","is_ca":false},{"name":"Richard A. Larson","is_ca":false},{"name":"Bruce D. Cheson","is_ca":false},{"name":"Charles A. Schiffer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02307593760935496,"gpt":0.2983763764993762,"spread":0.2753004388900212,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001473304,0.000509702,0.002091269,0.0005887185,0.0003541028,0.000615407,0.000541969,0.0006236772,0.007117078],"category_scores_gemma":[0.001671157,0.0002448628,0.001077867,0.0002725121,0.0004837474,0.0003536991,0.000321126,0.001320465,0.0008015094],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001126965,"about_ca_system_score_gemma":0.0008135561,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009021132,"about_ca_topic_score_gemma":0.002192511,"domain_scores_codex":[0.9992998,0.0003587654,0.00004042852,0.0001080981,0.00007498097,0.0001180978],"domain_scores_gemma":[0.9982876,0.0006575951,0.0001890243,0.0001105457,0.00008809368,0.0006672128],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7184547,0.01035997,0.007573861,0.001476592,0.001135656,0.0002158891,0.0002200743,0.002145351,0.01086767,0.000369928,0.002942852,0.2442375],"study_design_scores_gemma":[0.3389913,0.5875973,0.04315324,0.0006526566,0.002305883,0.0009972489,0.00009487186,0.003522985,0.009654082,0.0007666405,0.01220083,0.00006297472],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9714964,0.02063363,0.0007238548,0.0007919308,0.000640707,0.001141206,0.0003737596,0.0001216747,0.004076744],"genre_scores_gemma":[0.9932526,0.003334768,0.000625549,0.000481946,0.0003719526,0.0004701415,0.0002992925,0.00001352951,0.001150341],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007117078,"threshold_uncertainty_score":0.02380896,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2792666902","doi":"10.1056/nejmoa1713976","title":"Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":909,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; Jewish General Hospital","funders":"F. Hoffmann-La Roche; AbbVie","keywords":"Venetoclax; Rituximab; Bendamustine; Medicine; Internal medicine; Chronic lymphocytic leukemia; Oncology; Progression-free survival; Neutropenia; Leukemia; Gastroenterology; Immunology; Lymphoma; Chemotherapy","authors":[{"name":"John F. Seymour","is_ca":false},{"name":"Thomas J. Kipps","is_ca":false},{"name":"Barbara Eichhorst","is_ca":false},{"name":"Peter Hillmen","is_ca":false},{"name":"James D’Rozario","is_ca":false},{"name":"Sarit Assouline","is_ca":true},{"name":"Carolyn Owen","is_ca":true},{"name":"John F. Gerecitano","is_ca":false},{"name":"Tadeusz Robak","is_ca":false},{"name":"Javier de la Serna","is_ca":false},{"name":"Ulrich Jaeger","is_ca":false},{"name":"Guillaume Cartron","is_ca":false},{"name":"Marco Montillo","is_ca":false},{"name":"Rod Humerickhouse","is_ca":false},{"name":"Elizabeth A. Punnoose","is_ca":false},{"name":"Yan Li","is_ca":false},{"name":"Michelle Boyer","is_ca":false},{"name":"Kathryn Humphrey","is_ca":false},{"name":"Mehrdad Mobasher","is_ca":false},{"name":"Arnon P. Kater","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03256968068832229,"gpt":0.3346197826151289,"spread":0.3020501019268066,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001434805,0.0002953556,0.0009532692,0.0002302264,0.0001749549,0.0003293197,0.0003668039,0.0004618587,0.001970539],"category_scores_gemma":[0.001270265,0.0001235189,0.0005067137,0.0003256401,0.0003956826,0.0002649457,0.0001702772,0.0009430912,0.0001757357],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000501293,"about_ca_system_score_gemma":0.0005119296,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004788052,"about_ca_topic_score_gemma":0.001274579,"domain_scores_codex":[0.9994086,0.000401704,0.00003328092,0.00006561047,0.00004650341,0.00004439956],"domain_scores_gemma":[0.9990609,0.0004676508,0.0002439162,0.00004621573,0.00002620022,0.0001550938],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6269493,0.008497022,0.01627217,0.002149788,0.001771193,0.00033428,0.0002418443,0.002800499,0.01482153,0.0005678438,0.002284339,0.3233101],"study_design_scores_gemma":[0.6852775,0.2579869,0.04073714,0.0003270552,0.001102807,0.001107591,0.00007213061,0.002213513,0.002531672,0.0006139205,0.007994977,0.00003477353],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842505,0.01397001,0.0001903395,0.0001787981,0.00006196304,0.0002761763,0.00008867495,0.00001959077,0.0009638371],"genre_scores_gemma":[0.9955864,0.002939357,0.0004951567,0.0001938605,0.00009852014,0.0002253078,0.0001514863,0.000003388919,0.0003065651],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001970539,"threshold_uncertainty_score":0.007588029,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2948436219","doi":"10.1056/nejmoa1815281","title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":852,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"National Cancer Institute; Novo Nordisk Fonden","keywords":"Venetoclax; Obinutuzumab; Medicine; Ibrutinib; Internal medicine; Oncology; Cancer research; Chronic lymphocytic leukemia; Leukemia","authors":[{"name":"Kirsten Fischer","is_ca":false},{"name":"Othman Al‐Sawaf","is_ca":false},{"name":"Jasmin Bahlo","is_ca":false},{"name":"Anna‐Maria Fink","is_ca":false},{"name":"Maneesh Tandon","is_ca":false},{"name":"Mark Dixon","is_ca":false},{"name":"Sandra Robrecht","is_ca":false},{"name":"Simon Warburton","is_ca":false},{"name":"Kathryn Humphrey","is_ca":false},{"name":"Olga Samoylova","is_ca":false},{"name":"A. M. Liberati","is_ca":false},{"name":"Javier Pinilla‐Ibarz","is_ca":false},{"name":"Stephen Opat","is_ca":false},{"name":"Liliya Sivcheva","is_ca":false},{"name":"Katell Le Dû","is_ca":false},{"name":"Laura Fogliatto","is_ca":false},{"name":"Carsten Utoft Niemann","is_ca":false},{"name":"Robert Weinkove","is_ca":false},{"name":"Sue Robinson","is_ca":true},{"name":"Thomas J. Kipps","is_ca":false},{"name":"Sebastian Böettcher","is_ca":false},{"name":"Eugen Tausch","is_ca":false},{"name":"Rod Humerickhouse","is_ca":false},{"name":"Barbara Eichhorst","is_ca":false},{"name":"Clemens‐Martin Wendtner","is_ca":false},{"name":"Anton W. Langerak","is_ca":false},{"name":"Karl-Anton Kreuzer","is_ca":false},{"name":"Matthias Ritgen","is_ca":false},{"name":"Valentin Goede","is_ca":false},{"name":"Stephan Stilgenbauer","is_ca":false},{"name":"Mehrdad Mobasher","is_ca":false},{"name":"Michael Hallek","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.009446074225422615,"gpt":0.2713665505737163,"spread":0.2619204763482937,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001170426,0.0003250321,0.0008021895,0.0002237139,0.0003199693,0.0004239844,0.0003124209,0.0004692146,0.00175265],"category_scores_gemma":[0.0009682083,0.0001390778,0.000514428,0.0003819777,0.0003715653,0.0003143888,0.0002469904,0.0009661986,0.0001260402],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005463848,"about_ca_system_score_gemma":0.0008270087,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005598123,"about_ca_topic_score_gemma":0.001677678,"domain_scores_codex":[0.9996309,0.0001929994,0.00002517558,0.00005467014,0.00003711421,0.00005919296],"domain_scores_gemma":[0.9990366,0.0003397737,0.000277046,0.00004077895,0.00002931713,0.0002766647],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5465925,0.01223629,0.09570597,0.00185225,0.001529378,0.0006514881,0.000444757,0.002682252,0.01898932,0.0004462202,0.002156096,0.3167135],"study_design_scores_gemma":[0.374539,0.4370373,0.1625312,0.0005145794,0.001968524,0.003036677,0.0002051846,0.002784741,0.005294368,0.0006168155,0.01141325,0.00005841537],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.988325,0.01035541,0.00009747102,0.0001349476,0.00003294022,0.0001350596,0.0000901702,0.000009032887,0.0008199433],"genre_scores_gemma":[0.9973038,0.001658918,0.0003105311,0.000165807,0.00008256835,0.0001413801,0.0001517398,0.000001958543,0.0001832132],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00175265,"threshold_uncertainty_score":0.006189883,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3016538158","doi":"10.1016/s0140-6736(20)30262-2","title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":612,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"National Cancer Institute","keywords":"Obinutuzumab; Chlorambucil; Medicine; Chronic lymphocytic leukemia; Internal medicine; Gastroenterology; Oncology; Leukemia; Cyclophosphamide; Chemotherapy","authors":[{"name":"Jeff P. Sharman","is_ca":false},{"name":"Miklós Egyed","is_ca":false},{"name":"Wojciech Jurczak","is_ca":false},{"name":"Alan P Skarbnik","is_ca":false},{"name":"John M. Pagel","is_ca":false},{"name":"Ian W. Flinn","is_ca":false},{"name":"Manali Kamdar","is_ca":false},{"name":"Talha Munir","is_ca":false},{"name":"Renata Walewska","is_ca":false},{"name":"Gillian Corbett","is_ca":false},{"name":"Laura Fogliatto","is_ca":false},{"name":"Yair Herishanu","is_ca":false},{"name":"Versha Banerji","is_ca":true},{"name":"Steven Coutré","is_ca":false},{"name":"George Follows","is_ca":false},{"name":"Patricia Walker","is_ca":false},{"name":"Karin Karlsson","is_ca":false},{"name":"Paolo Ghia","is_ca":false},{"name":"Ann Janssens","is_ca":false},{"name":"Florence Cymbalista","is_ca":false},{"name":"Jennifer A. Woyach","is_ca":false},{"name":"Gilles Salles","is_ca":false},{"name":"William G. Wierda","is_ca":false},{"name":"Raquel Izumi","is_ca":false},{"name":"Veerendra Munugalavadla","is_ca":false},{"name":"Priti Patel","is_ca":false},{"name":"Min Hui Wang","is_ca":false},{"name":"Sofia Wong","is_ca":false},{"name":"John C. Byrd","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1071913197879008,"gpt":0.3732692195852925,"spread":0.2660778997973917,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001695761,0.002056092,0.003242653,0.0004051804,0.0004446088,0.001428271,0.001118151,0.001972771,0.008416586],"category_scores_gemma":[0.00201857,0.0006276712,0.002939559,0.0005500289,0.001397827,0.001293319,0.0005306936,0.0040063,0.001457622],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001139563,"about_ca_system_score_gemma":0.001090934,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002157669,"about_ca_topic_score_gemma":0.00528164,"domain_scores_codex":[0.9993357,0.0003599277,0.00003034081,0.0001100998,0.00004285964,0.0001210166],"domain_scores_gemma":[0.9991571,0.0002871734,0.0001837997,0.00006817948,0.00004269274,0.0002611992],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9846032,0.001226,0.0002311926,0.0007495635,0.001212646,0.00003202928,0.00003865422,0.000224028,0.00103914,0.0001454511,0.000987619,0.009510538],"study_design_scores_gemma":[0.9854531,0.01276234,0.0005037701,0.00003478167,0.0003807324,0.00002009219,0.00001256124,0.000118669,0.00007088778,0.0001565748,0.0004786792,0.000007849858],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9574988,0.02450997,0.001217709,0.001991095,0.002249459,0.004388575,0.002508934,0.0002918709,0.005343586],"genre_scores_gemma":[0.9736319,0.008419069,0.001859803,0.002520138,0.0008841968,0.004070534,0.002024328,0.00005569729,0.006534236],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008416586,"threshold_uncertainty_score":0.02815628,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2902706178","doi":"10.1016/s1470-2045(18)30788-5","title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":548,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"","keywords":"Obinutuzumab; Ibrutinib; Chlorambucil; Medicine; Oncology; Internal medicine; Open label; Chronic lymphocytic leukemia; Venetoclax; Clinical trial; Leukemia; Chemotherapy; Cyclophosphamide","authors":[{"name":"Carol Moreno","is_ca":false},{"name":"Richard Greil","is_ca":false},{"name":"Fatih Demırkan","is_ca":false},{"name":"Alessandra Tedeschi","is_ca":false},{"name":"Bertrand Anz","is_ca":false},{"name":"Loree Larratt","is_ca":true},{"name":"Martin Šimkovič","is_ca":false},{"name":"Olga Samoilova","is_ca":false},{"name":"Jan Novák","is_ca":false},{"name":"Dina Ben‐Yehuda","is_ca":false},{"name":"Владимир Стругов","is_ca":false},{"name":"Devinder Gill","is_ca":false},{"name":"John G. Gribben","is_ca":false},{"name":"Emily Hsu","is_ca":false},{"name":"Chih‐Jian Lih","is_ca":false},{"name":"Cathy Zhou","is_ca":false},{"name":"Fong Clow","is_ca":false},{"name":"Danelle F. James","is_ca":false},{"name":"Lori Styles","is_ca":false},{"name":"Ian W. Flinn","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1690966730335881,"gpt":0.4438783636128727,"spread":0.2747816905792846,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001462398,0.001979579,0.003468333,0.0003779269,0.0004069265,0.001551263,0.001166052,0.00165513,0.005730763],"category_scores_gemma":[0.001733493,0.0007009432,0.002485326,0.000450009,0.00125361,0.001186293,0.0005754878,0.003643284,0.001172406],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001186784,"about_ca_system_score_gemma":0.0008955845,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001854729,"about_ca_topic_score_gemma":0.003954011,"domain_scores_codex":[0.9994247,0.000284519,0.00002260446,0.0001014898,0.00003808169,0.0001285815],"domain_scores_gemma":[0.9991668,0.0002557518,0.0001643992,0.0000689516,0.00003927579,0.0003047369],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9818156,0.001803167,0.0003157477,0.0005681472,0.001014634,0.00002866028,0.00005916958,0.0003577573,0.001521963,0.00009603641,0.0006775176,0.01174151],"study_design_scores_gemma":[0.967922,0.02943417,0.001011344,0.00004505476,0.0004501471,0.00003096125,0.00002500306,0.0002207999,0.0001668872,0.0001230134,0.000557553,0.00001313253],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816235,0.01100809,0.0005463747,0.0008068221,0.000812888,0.001566061,0.001006618,0.0001610399,0.002468675],"genre_scores_gemma":[0.9863256,0.004221749,0.001231057,0.001177878,0.0004564673,0.001775668,0.001290912,0.0000418954,0.003478821],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005730763,"threshold_uncertainty_score":0.01917124,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2980937306","doi":"10.1038/s41375-019-0602-x","title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","year":2019,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":463,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"National Cancer Institute; TG Therapeutics; Astellas Pharma; BeiGene; Gilead Sciences; GlaxoSmithKline; Pharmacyclics; Genentech; Sunesis; Teva Pharmaceutical Industries; Celgene; AstraZeneca; Bristol-Myers Squibb","keywords":"Ibrutinib; Chlorambucil; Internal medicine; Neutropenia; Medicine; Chronic lymphocytic leukemia; IGHV@; Adverse effect; Hematology; Oncology; Gastroenterology; Leukemia; Chemotherapy; Cyclophosphamide","authors":[{"name":"Jan A. Burger","is_ca":false},{"name":"Paul M. Barr","is_ca":false},{"name":"Tadeusz Robak","is_ca":false},{"name":"Carolyn Owen","is_ca":true},{"name":"Paolo Ghia","is_ca":false},{"name":"Alessandra Tedeschi","is_ca":false},{"name":"Osnat Bairey","is_ca":false},{"name":"Peter Hillmen","is_ca":false},{"name":"Steven Coutré","is_ca":false},{"name":"Stephen Devereux","is_ca":false},{"name":"Sebastian Grosicki","is_ca":false},{"name":"Helen O. McCarthy","is_ca":false},{"name":"David Simpson","is_ca":false},{"name":"Fritz Offner","is_ca":false},{"name":"Carol Moreno","is_ca":false},{"name":"Sandra Dai","is_ca":false},{"name":"Indu Lal","is_ca":false},{"name":"James P. Dean","is_ca":false},{"name":"Thomas J. Kipps","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0243989745233313,"gpt":0.3168264164823156,"spread":0.2924274419589843,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004857673,0.0005813834,0.001803794,0.0004707979,0.0006384694,0.001609441,0.0006290513,0.001554435,0.001337224],"category_scores_gemma":[0.003196299,0.0003130238,0.002920721,0.0006381545,0.0004224122,0.001131834,0.0005777659,0.002499414,0.0004576696],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001083342,"about_ca_system_score_gemma":0.0008771886,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001334463,"about_ca_topic_score_gemma":0.002273757,"domain_scores_codex":[0.9989323,0.0003510555,0.00009544702,0.000162072,0.0002007857,0.0002583147],"domain_scores_gemma":[0.9961097,0.0006787207,0.001374022,0.000303306,0.000379777,0.001154577],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3671989,0.008195967,0.4638736,0.0008457054,0.009996315,0.0007443396,0.0005561061,0.003604116,0.0070372,0.0001861504,0.00507258,0.132689],"study_design_scores_gemma":[0.03348591,0.08509018,0.8662652,0.0002146805,0.006152929,0.0006650213,0.0001859802,0.001853184,0.001596962,0.0003473334,0.00402241,0.0001201903],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9885082,0.007259744,0.0002735038,0.0003525385,0.00005679307,0.0001517069,0.00217558,0.00003210226,0.0011898],"genre_scores_gemma":[0.993865,0.0009603171,0.0001256847,0.0005974881,0.00008384646,0.0001144868,0.003700422,0.000007775854,0.0005450536],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004857673,"threshold_uncertainty_score":0.02569014,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2191219754","doi":"10.1016/s1470-2045(15)00465-9","title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":410,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; McMaster University; Juravinski Cancer Centre","funders":"Janssen Research and Development","keywords":"Bendamustine; Medicine; Rituximab; Ibrutinib; Internal medicine; Chronic lymphocytic leukemia; Placebo; Oncology; Gastroenterology; Lymphoma; Leukemia; Pathology","authors":[{"name":"Asher Chanan‐Khan","is_ca":false},{"name":"Paula Cramer","is_ca":false},{"name":"Fatih Demırkan","is_ca":false},{"name":"Graeme Fraser","is_ca":true},{"name":"Rodrigo Santucci Silva","is_ca":false},{"name":"Sebastian Grosicki","is_ca":false},{"name":"Aleksander Pristupa","is_ca":false},{"name":"Ann Janssens","is_ca":false},{"name":"Jiřı́ Mayer","is_ca":false},{"name":"Nancy L. Bartlett","is_ca":false},{"name":"Marie‐Sarah Dilhuydy","is_ca":false},{"name":"Halyna Pylypenko","is_ca":false},{"name":"Javier Loscertales","is_ca":false},{"name":"Abraham Avigdor","is_ca":false},{"name":"Simon Rule","is_ca":false},{"name":"Diego Villa","is_ca":true},{"name":"Olga Samoilova","is_ca":false},{"name":"Panagiots Panagiotidis","is_ca":false},{"name":"André Goy","is_ca":false},{"name":"Anthony R. Mato","is_ca":false},{"name":"Miguel Arturo Pavlovsky","is_ca":false},{"name":"Claes Karlsson","is_ca":false},{"name":"Michelle Mahler","is_ca":false},{"name":"Mariya Salman","is_ca":false},{"name":"Steven Sun","is_ca":false},{"name":"Charles E. Phelps","is_ca":false},{"name":"Sriram Balasubramanian","is_ca":false},{"name":"Angela Howes","is_ca":false},{"name":"Michael Hallek","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1312919578447798,"gpt":0.3850341185845375,"spread":0.2537421607397577,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002410678,0.002802495,0.005522549,0.000853355,0.0006188602,0.001625436,0.001846992,0.003035712,0.007239156],"category_scores_gemma":[0.002196155,0.001553343,0.003113706,0.0006803245,0.002195848,0.001872978,0.0006992289,0.003790539,0.001712272],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001211391,"about_ca_system_score_gemma":0.001136711,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002112722,"about_ca_topic_score_gemma":0.002814974,"domain_scores_codex":[0.9989029,0.0005541773,0.00007125409,0.0002054966,0.00008288716,0.0001832764],"domain_scores_gemma":[0.9988299,0.0004020565,0.0002229839,0.0001050896,0.00006704393,0.0003728553],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9921428,0.002501667,0.0000866073,0.0002512972,0.0005324208,0.00001164828,0.00002072702,0.0001090599,0.001175599,0.00002935213,0.0001309648,0.003007716],"study_design_scores_gemma":[0.9634883,0.0353038,0.0003890404,0.00001514474,0.0003121189,0.000008384292,0.00001066099,0.0001204016,0.0001351081,0.00005025933,0.0001575171,0.000009410374],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9848744,0.007065066,0.0007339272,0.0005491765,0.001044239,0.00275928,0.0008293504,0.0001810419,0.001963501],"genre_scores_gemma":[0.9819409,0.00438544,0.001595566,0.001064877,0.0009457949,0.004092555,0.0009682103,0.00005753296,0.004949119],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007239156,"threshold_uncertainty_score":0.02421743,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2136242714","doi":"10.1200/jco.2005.05.0401","title":"Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":409,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lenalidomide; Neutropenia; Internal medicine; Fludarabine; Chronic lymphocytic leukemia; Refractory (planetary science); Rituximab; Gastroenterology; Adverse effect; Phases of clinical research; Progressive disease; Oncology; Surgery; Clinical trial; Leukemia; Multiple myeloma; Toxicity; Chemotherapy; Lymphoma; Cyclophosphamide","authors":[{"name":"Asher Chanan‐Khan","is_ca":true},{"name":"Kena C. Miller","is_ca":true},{"name":"Laurie Musial","is_ca":true},{"name":"David Lawrence","is_ca":true},{"name":"Swaminathan P. Iyer","is_ca":true},{"name":"Kenichi Takeshita","is_ca":true},{"name":"Carl W. Porter","is_ca":true},{"name":"David W. Goodrich","is_ca":true},{"name":"Zale P. Bernstein","is_ca":true},{"name":"Paul K. Wallace","is_ca":true},{"name":"David Spaner","is_ca":true},{"name":"Alice Mohr","is_ca":true},{"name":"Catriona Byrne","is_ca":true},{"name":"Francisco J. Hernandez‐Ilizaliturri","is_ca":true},{"name":"Cynthia Chrystal","is_ca":true},{"name":"Petr Starostik","is_ca":true},{"name":"Myron S. Czuczman","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08788936020811099,"gpt":0.4740014396404239,"spread":0.3861120794323129,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003037308,0.001060627,0.002024523,0.0003620133,0.0003781574,0.0008319716,0.0006962224,0.0009892951,0.001569457],"category_scores_gemma":[0.001362625,0.0003732922,0.001103307,0.0003850838,0.0007203646,0.0006122937,0.0002664169,0.001618198,0.0005325543],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007022906,"about_ca_system_score_gemma":0.001038674,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006948141,"about_ca_topic_score_gemma":0.001012684,"domain_scores_codex":[0.9989335,0.0006145171,0.00009545652,0.0001099017,0.0001273903,0.0001192119],"domain_scores_gemma":[0.9987715,0.0002620233,0.0002535232,0.000133218,0.00008526079,0.0004945457],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5625563,0.09422068,0.05702589,0.001454452,0.004399964,0.0006578626,0.0006332585,0.002323936,0.05105917,0.000186237,0.003610238,0.221872],"study_design_scores_gemma":[0.3788845,0.548499,0.06133073,0.00009859046,0.001011354,0.0007640218,0.00009430743,0.000898111,0.003505109,0.0001060538,0.0047575,0.00005064491],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916904,0.00490871,0.0003092995,0.0002164093,0.00005308661,0.001218515,0.0004815117,0.00004510166,0.001076998],"genre_scores_gemma":[0.991528,0.002710511,0.0009061405,0.0008135177,0.0002055673,0.001105188,0.001881048,0.00001732037,0.0008327664],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003037308,"threshold_uncertainty_score":0.01606297,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2275948481","doi":"10.1182/blood-2004-03-0796","title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":407,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Kingston General Hospital","funders":"State University of New York Upstate Medical University; University of North Carolina at Chapel Hill; University of Illinois at Urbana-Champaign; Virginia Commonwealth University; McGill University; Syracuse University; University of Pittsburgh; Memorial Sloan-Kettering Cancer Center; Johns Hopkins University; University of Rochester; University of Miami; York University; University of Missouri; Georgetown University; National Cancer Institute; Wake Forest University; University of Pennsylvania; Dartmouth College; State University of New York; University of Nebraska Medical Center; Kaiser Permanente; University of South Carolina; University of Minnesota; Massachusetts General Hospital; University of Pretoria; Ohio State University; D. Warren Brown Family Foundation; Leukemia and Lymphoma Society","keywords":"Fludarabine; Rituximab; Medicine; Internal medicine; Chronic lymphocytic leukemia; Oncology; Leukemia; Surgery; Chemotherapy; Lymphoma; Cyclophosphamide","authors":[{"name":"J. C. Byrd","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0119435218848345,"gpt":0.2820362234149799,"spread":0.2700927015301454,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002664959,0.0002299987,0.0005719594,0.0005977987,0.0002684726,0.000723746,0.0002682784,0.0003866358,0.000663543],"category_scores_gemma":[0.004264999,0.000190054,0.0007632396,0.0007337225,0.0003239413,0.0004138314,0.0002270025,0.0005005434,0.00008455337],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008763829,"about_ca_system_score_gemma":0.0004546749,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001895818,"about_ca_topic_score_gemma":0.005011685,"domain_scores_codex":[0.9989055,0.0004883559,0.0001068025,0.0001337162,0.0002510237,0.0001145021],"domain_scores_gemma":[0.996883,0.001425,0.001072327,0.0002031807,0.0001880661,0.000228464],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.02750106,0.0003909064,0.9215794,0.0001448989,0.002242937,0.0002831542,0.0001876647,0.0004304212,0.00179864,0.00007647478,0.0004934905,0.04487094],"study_design_scores_gemma":[0.001550652,0.007458004,0.984527,0.00003395429,0.001944661,0.001001882,0.00008573104,0.0004535302,0.0007316616,0.00005794704,0.002140371,0.00001466213],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968059,0.00258177,0.00007065729,0.00005250398,0.000005692802,0.00001358143,0.0001352659,0.000002563281,0.0003320455],"genre_scores_gemma":[0.9987483,0.000479346,0.00006742759,0.00007768095,0.00002925578,0.00001909641,0.0004673611,0.000001658169,0.0001097839],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002664959,"threshold_uncertainty_score":0.01409382,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3029637120","doi":"10.1200/jco.19.03355","title":"ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":362,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"","keywords":"Bendamustine; Idelalisib; Medicine; Rituximab; Chronic lymphocytic leukemia; Refractory (planetary science); Internal medicine; Oncology; Leukemia; Lymphoma; Ibrutinib","authors":[{"name":"Paolo Ghia","is_ca":false},{"name":"Andrzej Pluta","is_ca":false},{"name":"Małgorzata Wach","is_ca":false},{"name":"Daniel Lysák","is_ca":false},{"name":"Tomáš Kozák","is_ca":false},{"name":"Martin Šimkovič","is_ca":false},{"name":"Polina Kaplan","is_ca":false},{"name":"Iryna Kraychok","is_ca":false},{"name":"Árpád Illés","is_ca":false},{"name":"Javier de la Serna","is_ca":false},{"name":"Sean Dolan","is_ca":true},{"name":"Phillip L. Campbell","is_ca":false},{"name":"Gerardo Musuraca","is_ca":false},{"name":"Abraham Jacob","is_ca":false},{"name":"Eric J. Avery","is_ca":false},{"name":"Jae Hoon Lee","is_ca":false},{"name":"Wei Liang","is_ca":false},{"name":"Priti Patel","is_ca":false},{"name":"Cheng S. Quah","is_ca":false},{"name":"Wojciech Jurczak","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2071622178590186,"gpt":0.5057558719860992,"spread":0.2985936541270806,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002147524,0.002210519,0.002138454,0.0006047693,0.0004488692,0.001151824,0.001058885,0.001186161,0.005757434],"category_scores_gemma":[0.001536413,0.0005313787,0.001471911,0.0004181207,0.00120945,0.001068056,0.000621294,0.002957048,0.0009711274],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008588441,"about_ca_system_score_gemma":0.001301153,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007616371,"about_ca_topic_score_gemma":0.002397696,"domain_scores_codex":[0.9993087,0.0004254128,0.00003088712,0.0001000441,0.00004962004,0.00008529762],"domain_scores_gemma":[0.9990968,0.0001892411,0.0002233554,0.00005380446,0.00005023011,0.0003866543],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9786471,0.004329437,0.0006562803,0.0003368892,0.0005247095,0.00003115743,0.00002917725,0.0004361286,0.001335801,0.0001865375,0.001770716,0.01171608],"study_design_scores_gemma":[0.9589285,0.03733464,0.001135966,0.000022862,0.0002851037,0.00002815775,0.00001711301,0.0005323527,0.0002889922,0.0002335107,0.001183963,0.00000889562],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.970742,0.005977568,0.001171637,0.001499301,0.001133166,0.009811549,0.003299345,0.0003496839,0.006015638],"genre_scores_gemma":[0.9715133,0.003191135,0.002561045,0.002037353,0.0009846411,0.01136594,0.002990548,0.00004103008,0.005315019],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005757434,"threshold_uncertainty_score":0.01926047,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2130979463","doi":"10.1038/ng.479","title":"Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk","year":2009,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":355,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network; Mount Sinai Hospital; University of Toronto","funders":"National Center for Research Resources; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Allergy and Infectious Diseases; National Human Genome Research Institute; National Institute for Health and Care Research; Canadian Institutes of Health Research; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Versus Arthritis; National Heart, Lung, and Blood Institute","keywords":"Single-nucleotide polymorphism; Genome-wide association study; Biology; Genetics; Rheumatoid arthritis; Genetic association; Replication (statistics); Arthritis; Gene; Bioinformatics; Genotype; Immunology; Virology","authors":[{"name":"Soumya Raychaudhuri","is_ca":false},{"name":"Brian Thomson","is_ca":false},{"name":"Elaine F. Remmers","is_ca":false},{"name":"Stephen Eyre","is_ca":false},{"name":"Anne Hinks","is_ca":false},{"name":"Candace Guiducci","is_ca":false},{"name":"Joseph J. Catanese","is_ca":false},{"name":"Gang Xie","is_ca":true},{"name":"Eli A. Stahl","is_ca":false},{"name":"Robert Chen","is_ca":false},{"name":"Lars Alfredsson","is_ca":false},{"name":"Christopher I. Amos","is_ca":false},{"name":"Kristin Ardlie","is_ca":false},{"name":"Anne Barton","is_ca":false},{"name":"John Bowes","is_ca":false},{"name":"Noël P. Burtt","is_ca":false},{"name":"Monica Chang","is_ca":false},{"name":"Jonathan Coblyn","is_ca":false},{"name":"Karen H. Costenbader","is_ca":false},{"name":"Lindsey A. Criswell","is_ca":false},{"name":"J. Bart A. Crusius","is_ca":false},{"name":"Jing Cui","is_ca":false},{"name":"Phillip L. De Jager","is_ca":false},{"name":"Bo Ding","is_ca":false},{"name":"Paul Emery","is_ca":false},{"name":"Edward Flynn","is_ca":false},{"name":"Pille Harrison","is_ca":false},{"name":"Lynne J. Hocking","is_ca":false},{"name":"T. Huizinga","is_ca":false},{"name":"Daniel L. Kastner","is_ca":false},{"name":"Xiayi Ke","is_ca":false},{"name":"Fina Kurreeman","is_ca":false},{"name":"Annette T. Lee","is_ca":false},{"name":"Xiangdong Liu","is_ca":true},{"name":"Yonghong Li","is_ca":false},{"name":"Paul Martin","is_ca":false},{"name":"Ann W Morgan","is_ca":false},{"name":"Leonid Padyukov","is_ca":false},{"name":"David M. Reid","is_ca":false},{"name":"Mark Seielstad","is_ca":false},{"name":"Michael F. Seldin","is_ca":false},{"name":"Nancy A. Shadick","is_ca":false},{"name":"Sophia Steer","is_ca":false},{"name":"Paul P. Tak","is_ca":false},{"name":"Wendy Thomson","is_ca":false},{"name":"Annette H M van der Helm–van Mil","is_ca":false},{"name":"Irene E. van der Horst‐Bruinsma","is_ca":false},{"name":"Michael E. Weinblatt","is_ca":false},{"name":"Anthony G. Wilson","is_ca":false},{"name":"Gertjan Wolbink","is_ca":false},{"name":"P Wordsworth","is_ca":false},{"name":"David Altshuler","is_ca":false},{"name":"Elizabeth W. Karlson","is_ca":false},{"name":"René E. M. Toes","is_ca":false},{"name":"Niek de Vries","is_ca":false},{"name":"Ann B. Begovich","is_ca":false},{"name":"Katherine Siminovitch","is_ca":true},{"name":"Jane Worthington","is_ca":false},{"name":"Lars Klareskog","is_ca":false},{"name":"Peter K. Gregersen","is_ca":false},{"name":"Mark J. Daly","is_ca":false},{"name":"Robert M. Plenge","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007128330863492305,"gpt":0.253852568177397,"spread":0.2467242373139047,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000481917,0.0007915704,0.0005301774,0.001186888,0.0005095245,0.0004863648,0.0006117288,0.001061185,0.004368506],"category_scores_gemma":[0.002986598,0.0003733819,0.0005334182,0.0009667902,0.0004052607,0.0002291284,0.0002745193,0.0008878789,0.0004445848],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001864239,"about_ca_system_score_gemma":0.0001681293,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001531413,"about_ca_topic_score_gemma":0.001024219,"domain_scores_codex":[0.9993773,0.0002524351,0.00006315905,0.0001353489,0.0001010853,0.00007080835],"domain_scores_gemma":[0.997872,0.0009358337,0.0006222972,0.0001435645,0.0001141317,0.0003122904],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004955282,0.0003122981,0.9163643,0.00009281638,0.0008195107,0.007330504,0.00033894,0.0005586182,0.05825993,0.000488141,0.0006140243,0.00986572],"study_design_scores_gemma":[0.0002349173,0.0005109652,0.9804894,0.00002797708,0.000589395,0.01149862,0.0001860957,0.001836392,0.003173509,0.0007371124,0.0006859533,0.00002976302],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980305,0.0004721202,0.0003409192,0.0001215073,0.00002519912,0.000005796759,0.00009987224,0.00001874249,0.000885293],"genre_scores_gemma":[0.9991066,0.00008767853,0.0002984178,0.00003088338,0.00003411705,0.00000441383,0.0000632704,0.000007517132,0.0003671212],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004368506,"threshold_uncertainty_score":0.01461411,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3082899459","doi":"10.1016/s1470-2045(20)30443-5","title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":327,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"F. Hoffmann-La Roche; AbbVie","keywords":"Obinutuzumab; Chlorambucil; Venetoclax; Medicine; Internal medicine; Oncology; Chronic lymphocytic leukemia; Fludarabine; Open label; Clinical trial; Chemotherapy; Leukemia; Cyclophosphamide","authors":[{"name":"Othman Al‐Sawaf","is_ca":false},{"name":"Can Zhang","is_ca":false},{"name":"Maneesh Tandon","is_ca":false},{"name":"Arijit Sinha","is_ca":false},{"name":"Anna‐Maria Fink","is_ca":false},{"name":"Sandra Robrecht","is_ca":false},{"name":"Olga Samoylova","is_ca":false},{"name":"Anna Marina Liberati","is_ca":false},{"name":"Javier Pinilla‐Ibarz","is_ca":false},{"name":"Stephen Opat","is_ca":false},{"name":"Liliya Sivcheva","is_ca":false},{"name":"Katell Le Dû","is_ca":false},{"name":"Laura Fogliatto","is_ca":false},{"name":"Carsten Utoft Niemann","is_ca":false},{"name":"Robert Weinkove","is_ca":false},{"name":"Sue Robinson","is_ca":true},{"name":"Thomas J. Kipps","is_ca":false},{"name":"Eugen Tausch","is_ca":false},{"name":"William Schary","is_ca":false},{"name":"Matthias Ritgen","is_ca":false},{"name":"Clemens‐Martin Wendtner","is_ca":false},{"name":"Karl-Anton Kreuzer","is_ca":false},{"name":"Barbara Eichhorst","is_ca":false},{"name":"Stephan Stilgenbauer","is_ca":false},{"name":"Michael Hallek","is_ca":false},{"name":"Kirsten Fischer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2241489103395237,"gpt":0.4279868705273332,"spread":0.2038379601878094,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00148085,0.001532519,0.002662885,0.0003866584,0.000415278,0.001413886,0.0009794747,0.001558324,0.005409391],"category_scores_gemma":[0.001987944,0.0004534794,0.002262603,0.0004651858,0.001117537,0.001204776,0.0004278537,0.003505845,0.0009871573],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001028983,"about_ca_system_score_gemma":0.0009469991,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001819495,"about_ca_topic_score_gemma":0.004128269,"domain_scores_codex":[0.9993609,0.000347679,0.00002363953,0.00009422802,0.00003810647,0.0001355254],"domain_scores_gemma":[0.9989544,0.0003760408,0.0002240392,0.00007618161,0.00004274354,0.0003266386],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9727518,0.002307646,0.0004513965,0.0005409778,0.0009708174,0.00003921522,0.00006544655,0.0003461227,0.001615592,0.000119805,0.0007176477,0.02007349],"study_design_scores_gemma":[0.9533328,0.04303278,0.001772502,0.00005847692,0.0004492271,0.00004312171,0.00003229987,0.0002498066,0.0002210573,0.000190349,0.0006029886,0.00001455597],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842519,0.01040043,0.0004670409,0.0006932714,0.0006418373,0.000953879,0.0008021313,0.0001067421,0.001682734],"genre_scores_gemma":[0.9877821,0.004091765,0.0009764149,0.0008807236,0.000353008,0.001079498,0.001079184,0.00002980262,0.00372745],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005409391,"threshold_uncertainty_score":0.01809621,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2944582362","doi":"10.1056/nejmoa1901981","title":"Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":320,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"NeuroRx Research (Canada); University of Toronto; St. Michael's Hospital","funders":"Merck KGaA","keywords":"Placebo; Multiple sclerosis; Medicine; Bruton's tyrosine kinase; Internal medicine; Clinical trial; Oncology; Pharmacology; Alternative medicine; Immunology; Pathology; Tyrosine kinase","authors":[{"name":"Xavier Montalbán","is_ca":true},{"name":"Douglas L. Arnold","is_ca":true},{"name":"Martin S. Weber","is_ca":true},{"name":"Ivan Staikov","is_ca":true},{"name":"Karolina Piasecka‐Stryczynska","is_ca":true},{"name":"Jonathan Willmer","is_ca":true},{"name":"Emily C. Martin","is_ca":true},{"name":"Fernando Dangond","is_ca":true},{"name":"Sana Syed","is_ca":true},{"name":"Jerry S. Wolinsky","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04527378136246739,"gpt":0.3088913223947608,"spread":0.2636175410322934,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001699147,0.001479446,0.004131489,0.0005801672,0.0005148702,0.00125432,0.0008335682,0.002395647,0.01341673],"category_scores_gemma":[0.001937218,0.0005172045,0.001456673,0.0004681571,0.001040466,0.001167787,0.0004105776,0.002765635,0.00151474],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007166953,"about_ca_system_score_gemma":0.001039135,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007715597,"about_ca_topic_score_gemma":0.001559986,"domain_scores_codex":[0.9992355,0.0003681484,0.00006869629,0.0001553826,0.00006730195,0.000104919],"domain_scores_gemma":[0.9991823,0.0002282744,0.0001832376,0.0000482289,0.00007674252,0.0002812766],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9821331,0.002224085,0.0002118401,0.0009691784,0.000679276,0.00003821146,0.00001810416,0.0001292219,0.001034384,0.0000948467,0.0008973317,0.01157039],"study_design_scores_gemma":[0.9634924,0.03353767,0.001176125,0.0000650861,0.0003130414,0.00002713915,0.00001346782,0.0001777916,0.0001507254,0.0001120717,0.0009277569,0.000006786514],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9310045,0.04007076,0.001189274,0.003467776,0.004285216,0.006857395,0.002957618,0.0005245756,0.009642853],"genre_scores_gemma":[0.9728585,0.007937401,0.001421224,0.002779661,0.001439931,0.005604498,0.001691465,0.00003304178,0.00623419],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01341673,"threshold_uncertainty_score":0.04488343,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3007925874","doi":"10.1182/blood.2019002936","title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":320,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health; Juno Therapeutics; University of British Columbia; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Celgene","keywords":"Ibrutinib; Bruton's tyrosine kinase; Medicine; Internal medicine; Oncology; Chronic lymphocytic leukemia; Leukemia; Tyrosine kinase; Receptor","authors":[{"name":"Jordan Gauthier","is_ca":false},{"name":"Alexandre V. Hirayama","is_ca":false},{"name":"Janaki Purushe","is_ca":false},{"name":"Kevin A. Hay","is_ca":true},{"name":"James Lymp","is_ca":false},{"name":"Daniel H. Li","is_ca":false},{"name":"Cecilia C.S. Yeung","is_ca":false},{"name":"Alyssa Sheih","is_ca":false},{"name":"Barbara S. Pender","is_ca":false},{"name":"Reed M. Hawkins","is_ca":false},{"name":"Aesha Vakil","is_ca":false},{"name":"Tinh-Doan Phi","is_ca":false},{"name":"Rachel N. Steinmetz","is_ca":false},{"name":"Mazyar Shadman","is_ca":false},{"name":"Stanley R. Riddell","is_ca":false},{"name":"David G. Maloney","is_ca":false},{"name":"Cameron J. Turtle","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02987095647810029,"gpt":0.2892506916692684,"spread":0.2593797351911681,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001064244,0.000434719,0.0006499029,0.0002161826,0.0002823674,0.0004656152,0.0004368357,0.0002736199,0.0005723046],"category_scores_gemma":[0.001012897,0.0001864505,0.0004679809,0.0001711678,0.000395477,0.0003990048,0.0003118395,0.0006363956,0.0001766383],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004173221,"about_ca_system_score_gemma":0.0005175908,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000800156,"about_ca_topic_score_gemma":0.0008472182,"domain_scores_codex":[0.9996154,0.0001509688,0.00003143219,0.00006633457,0.00004822579,0.00008753683],"domain_scores_gemma":[0.9996305,0.0001301495,0.0000742004,0.00006758156,0.00002146862,0.00007606302],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.07828206,0.01358409,0.0605382,0.0003900297,0.0003072308,0.00211873,0.0006532538,0.006530389,0.4932882,0.0003906234,0.0007440231,0.3431732],"study_design_scores_gemma":[0.01637712,0.4988827,0.1317781,0.00008820337,0.001214361,0.004255905,0.000272539,0.0214843,0.3185768,0.0003231057,0.006664048,0.00008274276],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9983399,0.0004505407,0.0006844251,0.00003237835,0.00001051279,0.00007820305,0.00003231453,0.00002937311,0.0003423443],"genre_scores_gemma":[0.9993724,0.0001098851,0.0002968487,0.00001870587,0.00001330763,0.00005944611,0.00005376776,0.000004118597,0.00007149203],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001064244,"threshold_uncertainty_score":0.005628288,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2070487917","doi":"10.3109/10428194.2015.1022770","title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","year":2015,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":307,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Gilead Sciences (Canada)","funders":"Gilead Sciences","keywords":"Idelalisib; Medicine; Adverse effect; Internal medicine; Diarrhea; Intensive care medicine; Ibrutinib","authors":[{"name":"Steven Coutré","is_ca":false},{"name":"Jacqueline C. Barrientos","is_ca":false},{"name":"Jennifer R. Brown","is_ca":false},{"name":"Sven de Vos","is_ca":false},{"name":"Richard R. Furman","is_ca":false},{"name":"Michael J. Keating","is_ca":false},{"name":"Daniel Li","is_ca":true},{"name":"Susan O’Brien","is_ca":false},{"name":"John M. Pagel","is_ca":false},{"name":"Martin Poleski","is_ca":false},{"name":"Jeff P. Sharman","is_ca":false},{"name":"Nai-Shun Yao","is_ca":false},{"name":"Andrew D. Zelenetz","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07781209335968814,"gpt":0.3511248248391235,"spread":0.2733127314794354,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004513519,0.00069309,0.001383617,0.001065454,0.0003179538,0.00121972,0.001498956,0.002131157,0.004303499],"category_scores_gemma":[0.008271046,0.0001942809,0.001751493,0.001059927,0.0003278549,0.001427125,0.0006424335,0.002068335,0.001489663],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007747761,"about_ca_system_score_gemma":0.001935666,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001169745,"about_ca_topic_score_gemma":0.003344555,"domain_scores_codex":[0.998014,0.0007074039,0.0004731428,0.0001441158,0.0005783477,0.00008299271],"domain_scores_gemma":[0.9951069,0.001929341,0.0008282053,0.00006759149,0.001916658,0.0001512773],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001119702,0.00003418628,0.0004342863,0.02418848,0.0003062325,0.0004299228,0.0001107053,0.000260691,0.0006738545,0.001226054,0.1771192,0.7951044],"study_design_scores_gemma":[0.0001288096,0.0001096043,0.001557151,0.04030741,0.0008814777,0.002483079,0.0001580244,0.0002094507,0.0005631413,0.002248794,0.9512977,0.00005529176],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0005208586,0.9627418,0.001559644,0.0252962,0.002849199,0.0001587224,0.0003058276,0.00003805174,0.006529686],"genre_scores_gemma":[0.00461683,0.9735811,0.002442045,0.01360493,0.002896313,0.0001334838,0.0003714413,0.000009478773,0.002344418],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004513519,"threshold_uncertainty_score":0.02387005,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2074584895","doi":"10.1182/blood-2010-03-275420","title":"Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":304,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"National Cancer Institute; Amgen","keywords":"Alemtuzumab; Fludarabine; Medicine; Transplantation; Internal medicine; Chronic lymphocytic leukemia; Minimal residual disease; Oncology; Leukemia; Immunology; Cyclophosphamide; Chemotherapy","authors":[{"name":"Peter Dreger","is_ca":false},{"name":"Hartmut Döhner","is_ca":false},{"name":"Matthias Ritgen","is_ca":false},{"name":"Sebastian Böttcher","is_ca":false},{"name":"Raymonde Busch","is_ca":false},{"name":"Sascha Dietrich","is_ca":false},{"name":"Donald Bunjes","is_ca":false},{"name":"Sandra Cohen","is_ca":true},{"name":"Jörg Schubert","is_ca":false},{"name":"Ute Hegenbart","is_ca":false},{"name":"Dietrich W. Beelen","is_ca":false},{"name":"Matthias Zeis","is_ca":false},{"name":"Michael Stadler","is_ca":false},{"name":"Justin Hasenkamp","is_ca":false},{"name":"Lutz Uharek","is_ca":false},{"name":"Christof Scheid","is_ca":false},{"name":"Andreas Humpe","is_ca":false},{"name":"Thorsten Zenz","is_ca":false},{"name":"Dirk Winkler","is_ca":false},{"name":"Michael Hallek","is_ca":false},{"name":"Michael Kneba","is_ca":false},{"name":"Norbert Schmitz","is_ca":false},{"name":"Stephan Stilgenbauer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01688420731791969,"gpt":0.3061873217614207,"spread":0.289303114443501,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001668619,0.0006550783,0.0006385777,0.0001743313,0.0001699875,0.0005781116,0.0003007342,0.0004850042,0.0009078148],"category_scores_gemma":[0.0006510061,0.0001098233,0.0006174651,0.0001981606,0.0005176027,0.0002893222,0.0002609653,0.0008054909,0.000160821],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005036077,"about_ca_system_score_gemma":0.0004413589,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005092776,"about_ca_topic_score_gemma":0.001254843,"domain_scores_codex":[0.9994597,0.0003918894,0.00001758757,0.0000384128,0.0000327775,0.00005959019],"domain_scores_gemma":[0.9995178,0.0001147374,0.0001455942,0.00003990423,0.00001934144,0.0001626787],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7846661,0.007741041,0.04782837,0.0007429996,0.002160603,0.0002186604,0.0002090085,0.003842713,0.02561385,0.0004573683,0.003168953,0.1233504],"study_design_scores_gemma":[0.5208326,0.3085159,0.1505271,0.0001995775,0.002567877,0.0005602132,0.0001259253,0.003119267,0.006201935,0.0006953174,0.006591859,0.00006236183],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969284,0.002134367,0.0001054939,0.0002085447,0.00001919174,0.0000881322,0.0001657205,0.00001036825,0.0003398346],"genre_scores_gemma":[0.9966745,0.0009794306,0.0002810443,0.0004364115,0.00007463151,0.0002349367,0.0008774666,0.00000650106,0.0004349219],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001668619,"threshold_uncertainty_score":0.008824587,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2033489247","doi":"10.1073/pnas.0406927102","title":"Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap","year":2004,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":303,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Leukemia and Lymphoma Society; University of Rochester; National Cancer Institute; National Institutes of Health; Valeant Pharmaceuticals International; Harvard University","keywords":"EIF4E; Guanosine; Translation (biology); Messenger RNA; Biology; Ribavirin; Protein biosynthesis; Cancer research; Cell biology; Biochemistry; Gene","authors":[{"name":"Alex Kentsis","is_ca":false},{"name":"Ivan Topisirović","is_ca":false},{"name":"Biljana Čuljković","is_ca":false},{"name":"Ling Shao","is_ca":false},{"name":"Katherine L. B. Borden","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03186481578050641,"gpt":0.3307340918583351,"spread":0.2988692760778287,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008472762,0.0001764732,0.0001199015,0.000110451,0.00008906869,0.0001618844,0.0001133616,0.0001398743,0.0009720307],"category_scores_gemma":[0.00008201961,0.00007022794,0.0001039638,0.00005827148,0.0002029608,0.00007272357,0.0001117589,0.0002944373,0.0001718678],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001663648,"about_ca_system_score_gemma":0.000099382,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002718688,"about_ca_topic_score_gemma":0.0004810929,"domain_scores_codex":[0.9999278,0.0000223734,0.000004247457,0.00001003048,0.00001465808,0.00002090572],"domain_scores_gemma":[0.9999568,0.00001069195,0.0000128928,0.00000630644,0.000002603794,0.00001065798],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001697486,0.00005424886,0.0001315882,0.00001703872,0.000002932241,0.00002030803,0.000007626957,0.0000872949,0.9973881,0.0001360679,0.00004462432,0.001940384],"study_design_scores_gemma":[0.00006831663,0.001289542,0.003741744,0.000004918342,0.000008061569,0.0001963591,0.00001933293,0.001149904,0.9891775,0.00006771088,0.004273043,0.000003677652],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995796,0.0008613103,0.001045407,0.00007684998,0.00002409343,0.00002157202,0.00007805841,0.00007912207,0.00201763],"genre_scores_gemma":[0.9977049,0.0003282789,0.0006116609,0.00002673858,0.000007606967,0.00001807733,0.0001495416,0.000008312632,0.001144818],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009720307,"threshold_uncertainty_score":0.003251791,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2902460563","doi":"10.1200/jco.18.01580","title":"Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":301,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"Genentech; Universiteit van Amsterdam","keywords":"Venetoclax; Rituximab; Bendamustine; Medicine; Internal medicine; Minimal residual disease; Hazard ratio; Gastroenterology; Neutropenia; Refractory (planetary science); Chronic lymphocytic leukemia; Oncology; Leukemia; Chemotherapy; Lymphoma; Confidence interval","authors":[{"name":"Arnon P. Kater","is_ca":false},{"name":"John F. Seymour","is_ca":false},{"name":"Peter Hillmen","is_ca":false},{"name":"Barbara Eichhorst","is_ca":false},{"name":"Anton W. Langerak","is_ca":false},{"name":"Carolyn Owen","is_ca":true},{"name":"Maria Verdugo","is_ca":false},{"name":"Jenny Wu","is_ca":false},{"name":"Elizabeth A. Punnoose","is_ca":false},{"name":"Yanwen Jiang","is_ca":false},{"name":"Jue Wang","is_ca":false},{"name":"Michelle Boyer","is_ca":false},{"name":"Kathryn Humphrey","is_ca":false},{"name":"Mehrdad Mobasher","is_ca":false},{"name":"Thomas J. Kipps","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07805887314922061,"gpt":0.4367975780317877,"spread":0.3587387048825671,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003593471,0.0005511527,0.001397516,0.0002066482,0.0002574236,0.0006516653,0.0005302439,0.0005957988,0.0009839953],"category_scores_gemma":[0.001585879,0.0002395516,0.001068581,0.0002487032,0.0005133829,0.0003865744,0.0002189793,0.001452608,0.0002381313],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006169931,"about_ca_system_score_gemma":0.0005767698,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006481885,"about_ca_topic_score_gemma":0.001885528,"domain_scores_codex":[0.9990946,0.0005834915,0.00003496191,0.00008875153,0.00008461448,0.000113607],"domain_scores_gemma":[0.9985454,0.0003658062,0.0004649846,0.000211733,0.00006091074,0.0003511502],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7309656,0.01273608,0.06798893,0.0006564253,0.003098198,0.0002889714,0.0002789529,0.001647705,0.02357269,0.000242197,0.002940898,0.1555833],"study_design_scores_gemma":[0.29964,0.4620801,0.2234658,0.0001368572,0.002388545,0.0006418587,0.00008961491,0.001624259,0.003517412,0.000308867,0.006051373,0.00005538079],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961164,0.002503879,0.0001150668,0.0001045154,0.00003048222,0.0001806595,0.0002462431,0.00001487735,0.0006878038],"genre_scores_gemma":[0.9971602,0.0007624477,0.0002729826,0.0002832426,0.00008917148,0.0002369679,0.0005617186,0.000006181457,0.0006271697],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003593471,"threshold_uncertainty_score":0.01900434,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2558871324","doi":"10.1182/blood-2016-01-689422","title":"Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":289,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network; University of Alberta; University of Manitoba","funders":"National Cancer Institute; Cancer Research UK","keywords":"Medicine; Intensive care medicine; Pancytopenia; Minimal residual disease; Clinical trial; Disease; Transplantation; Disease management; Quality of life (healthcare); Leukemia; Immunology; Internal medicine; Nursing","authors":[{"name":"Michael R. Grever","is_ca":false},{"name":"Omar Abdel‐Wahab","is_ca":false},{"name":"Leslie A. Andritsos","is_ca":false},{"name":"Versha Banerji","is_ca":true},{"name":"Jacqueline C. Barrientos","is_ca":false},{"name":"James S. Blachly","is_ca":false},{"name":"Timothy G. Call","is_ca":false},{"name":"Daniel Catovsky","is_ca":false},{"name":"Claire Dearden","is_ca":false},{"name":"Judit Demeter","is_ca":false},{"name":"Monica Else","is_ca":false},{"name":"Francesco Forconi","is_ca":false},{"name":"Alessandro Gozzetti","is_ca":false},{"name":"Anthony D. Ho","is_ca":false},{"name":"James B. Johnston","is_ca":true},{"name":"Jeffrey A. Jones","is_ca":false},{"name":"Gunnar Juliusson","is_ca":false},{"name":"Eric H. Kraut","is_ca":false},{"name":"Robert J. Kreitman","is_ca":false},{"name":"Loree Larratt","is_ca":true},{"name":"Francesco Lauria","is_ca":false},{"name":"Gerard Lozanski","is_ca":false},{"name":"Emili Montserrat","is_ca":false},{"name":"Sameer A. Parikh","is_ca":false},{"name":"Jae H. Park","is_ca":false},{"name":"Aaron Polliack","is_ca":false},{"name":"Graeme Quest","is_ca":true},{"name":"Farhad Ravandi","is_ca":false},{"name":"Tadeusz Robak","is_ca":false},{"name":"Alan Saven","is_ca":false},{"name":"John F. Seymour","is_ca":false},{"name":"Tamar Tadmor","is_ca":false},{"name":"Martin S. Tallman","is_ca":false},{"name":"Constantine S. Tam","is_ca":false},{"name":"Enrico Tiacci","is_ca":false},{"name":"Xavier Troussard","is_ca":false},{"name":"Clive S. Zent","is_ca":false},{"name":"Thorsten Zenz","is_ca":false},{"name":"Pier Luigi Zinzani","is_ca":false},{"name":"Brunangelo Falini","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04892216517246414,"gpt":0.3103862414170301,"spread":0.261464076244566,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01882178,0.001316168,0.001849849,0.005350318,0.00238865,0.002316621,0.00618171,0.008088598,0.007278106],"category_scores_gemma":[0.03688518,0.0007562519,0.003468588,0.003191063,0.001487178,0.002143487,0.003124799,0.008379106,0.005151193],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004355894,"about_ca_system_score_gemma":0.01705966,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01272052,"about_ca_topic_score_gemma":0.02068269,"domain_scores_codex":[0.9810148,0.009548895,0.004895636,0.0004394911,0.003147918,0.0009531658],"domain_scores_gemma":[0.9581294,0.009060786,0.003313552,0.0009059558,0.02607902,0.002511268],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001105859,0.0003601558,0.002957275,0.002888035,0.0001001697,0.002046394,0.00114557,0.001494705,0.0009939196,0.01228522,0.6631913,0.3124267],"study_design_scores_gemma":[0.0002147799,0.0001463877,0.005094438,0.01502835,0.0001689854,0.003472132,0.00134934,0.001373462,0.000604819,0.01548179,0.956951,0.0001145163],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"methods","genre_scores_codex":[0.007409807,0.1330843,0.1117394,0.5509126,0.02505815,0.01259443,0.004221193,0.001714476,0.1532657],"genre_scores_gemma":[0.04989493,0.116911,0.6371738,0.1052325,0.007829173,0.01961892,0.01708126,0.0004634728,0.04579494],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.01882178,"threshold_uncertainty_score":0.09954023,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2151979638","doi":"10.1634/theoncologist.10-5-345","title":"HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum","year":2005,"lang":"en","type":"review","venue":"The Oncologist","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital Notre-Dame","funders":"National Cancer Institute; Genentech; F. Hoffmann-La Roche","keywords":"Rash; Medicine; Dermatology; Acne; EGFR inhibitors; Adverse effect; Etiology; Epidermal growth factor receptor; Pathology; Internal medicine; Cancer","authors":[{"name":"Román Pérez-Soler","is_ca":false},{"name":"Jean Pierre Delord","is_ca":false},{"name":"Allan C. Halpern","is_ca":false},{"name":"Karen Kelly","is_ca":false},{"name":"James G. Krueger","is_ca":false},{"name":"B. Massuti Sureda","is_ca":false},{"name":"Joachim von Pawel","is_ca":false},{"name":"Jennifer S. Temel","is_ca":false},{"name":"Salvatore Siena","is_ca":false},{"name":"Denis Soulières","is_ca":true},{"name":"Leonard B. Saltz","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06765387642643766,"gpt":0.3690442441056063,"spread":0.3013903676791686,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01181177,0.0006815272,0.00117344,0.001895299,0.00146057,0.004251596,0.001445638,0.003104002,0.03582477],"category_scores_gemma":[0.03664202,0.0002681963,0.002166991,0.001341184,0.0006488127,0.005587744,0.003231065,0.005174202,0.006467137],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002555605,"about_ca_system_score_gemma":0.007034408,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003102523,"about_ca_topic_score_gemma":0.006163697,"domain_scores_codex":[0.9963187,0.001472266,0.0003968102,0.0001768423,0.00105986,0.0005754303],"domain_scores_gemma":[0.9625424,0.008081742,0.002943696,0.0007698667,0.01462297,0.01103939],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003560042,0.0004224794,0.0132695,0.001597038,0.00004518508,0.0002774334,0.0001747519,0.0002481892,0.000110548,0.002134702,0.4993369,0.4820273],"study_design_scores_gemma":[0.0007392232,0.001499204,0.05603364,0.02247491,0.0004883268,0.00223189,0.003382989,0.00217131,0.0004172101,0.02360029,0.886731,0.000229889],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.01350021,0.1555303,0.007363035,0.7403177,0.02911646,0.0008176373,0.003428553,0.001035058,0.04889118],"genre_scores_gemma":[0.1576794,0.3784462,0.05650752,0.2382395,0.09181954,0.003446581,0.01825493,0.0007566652,0.05484966],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.03582477,"threshold_uncertainty_score":0.1198458,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4224138250","doi":"10.1182/bloodadvances.2021006434","title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia ","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":269,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"Pharmacyclics","keywords":"Ibrutinib; Chlorambucil; Chronic lymphocytic leukemia; Medicine; Internal medicine; Hazard ratio; Adverse effect; Oncology; Confidence interval; Leukemia; Gastroenterology; Chemotherapy; Cyclophosphamide","authors":[{"name":"Paul M. Barr","is_ca":false},{"name":"Carolyn Owen","is_ca":true},{"name":"Tadeusz Robak","is_ca":false},{"name":"Alessandra Tedeschi","is_ca":false},{"name":"Osnat Bairey","is_ca":false},{"name":"Jan A. Burger","is_ca":false},{"name":"Peter Hillmen","is_ca":false},{"name":"Steven Coutré","is_ca":false},{"name":"Claire Dearden","is_ca":false},{"name":"Sebastian Grosicki","is_ca":false},{"name":"Helen O. McCarthy","is_ca":false},{"name":"Jianyong Li","is_ca":false},{"name":"Fritz Offner","is_ca":false},{"name":"Carol Moreno","is_ca":false},{"name":"Cathy Zhou","is_ca":false},{"name":"Emily Hsu","is_ca":false},{"name":"Anita Szőke","is_ca":false},{"name":"Thomas J. Kipps","is_ca":false},{"name":"Paolo Ghia","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01781755912526684,"gpt":0.2833469322780211,"spread":0.2655293731527543,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002472379,0.0006561411,0.001707131,0.0006124551,0.0009711698,0.001054651,0.000611423,0.00122119,0.002617664],"category_scores_gemma":[0.003530589,0.0003010009,0.001680652,0.0005373245,0.0003835275,0.001182446,0.00112567,0.002285273,0.0008554033],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007960469,"about_ca_system_score_gemma":0.0006112352,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001755162,"about_ca_topic_score_gemma":0.002593437,"domain_scores_codex":[0.9990693,0.0002674515,0.00008372154,0.0001866923,0.0001556293,0.0002371767],"domain_scores_gemma":[0.9967213,0.0007560984,0.000765833,0.0003670178,0.0004507133,0.0009390733],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2248743,0.005273222,0.5464643,0.0007813183,0.003510076,0.002608471,0.0006500144,0.003351319,0.008932834,0.000261476,0.01160098,0.1916919],"study_design_scores_gemma":[0.01309447,0.05591973,0.9020588,0.0001923526,0.004438086,0.001764063,0.0002115977,0.001333788,0.003010732,0.0005388398,0.01730367,0.0001337708],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9719786,0.008548208,0.001000292,0.0005272393,0.0001300108,0.0005451738,0.01174254,0.00009392605,0.005434043],"genre_scores_gemma":[0.974075,0.001214128,0.0004518749,0.0007901881,0.0001393786,0.0005153986,0.01993717,0.00002341175,0.002853457],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002617664,"threshold_uncertainty_score":0.01307541,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2889729436","doi":"10.1016/j.molcel.2018.08.005","title":"Structural Basis for Regulation of Phosphoinositide Kinases and Their Involvement in Human Disease","year":2018,"lang":"en","type":"review","venue":"Molecular Cell","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":266,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Victoria","funders":"Canadian Institutes of Health Research","keywords":"Biology; Kinase; Disease; Protein-Serine-Threonine Kinases; Phosphoinositide 3-kinase; Cell biology; Human disease; Computational biology; Signal transduction; Protein kinase A; Genetics; PI3K/AKT/mTOR pathway; Gene; Internal medicine","authors":[{"name":"John E. Burke","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04109922541070341,"gpt":0.3339861591482495,"spread":0.292886933737546,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033981,0.0005762845,0.0006764788,0.0008572004,0.0001837905,0.0007454118,0.0007515856,0.0007038829,0.001879745],"category_scores_gemma":[0.000355224,0.0001788019,0.000265316,0.001051511,0.0005442003,0.0009471104,0.0005830597,0.001293966,0.001047548],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00059047,"about_ca_system_score_gemma":0.0008454125,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004801979,"about_ca_topic_score_gemma":0.000634146,"domain_scores_codex":[0.9999231,0.000009841478,0.00001105667,0.00001716471,0.00002510135,0.00001365074],"domain_scores_gemma":[0.9999064,0.00003224194,0.00002211073,0.000005108071,0.0000243857,0.000009782578],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002665872,0.00008880959,0.0003933042,0.01439932,0.0001244244,0.0006417913,0.0001129659,0.001133366,0.01972479,0.02268337,0.02344646,0.9169849],"study_design_scores_gemma":[0.0000267858,0.00007008493,0.000769401,0.001101914,0.0001077636,0.001173231,0.00006938213,0.0001503094,0.003724983,0.006231747,0.9865574,0.00001701966],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000412036,0.9974374,0.0002620344,0.0004396633,0.0001959528,0.000004554515,0.00002852537,0.000008358442,0.001211465],"genre_scores_gemma":[0.002403888,0.9965143,0.0002302884,0.0001485748,0.0001422227,0.0000048991,0.00004549773,0.00000103094,0.0005094863],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.001879745,"threshold_uncertainty_score":0.006288409,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2739393823","doi":"10.3324/haematol.2017.171041","title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","year":2017,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":258,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"National Cancer Institute; Pharmacyclics","keywords":"Ibrutinib; Medicine; Internal medicine; Discontinuation; Mantle cell lymphoma; Atrial fibrillation; Cumulative incidence; Adverse effect; Chronic lymphocytic leukemia; Hazard ratio; Oncology; Confidence interval; Leukemia; Lymphoma; Cohort","authors":[{"name":"Jennifer R. Brown","is_ca":false},{"name":"Javid J. Moslehi","is_ca":false},{"name":"Susan O’Brien","is_ca":false},{"name":"Paolo Ghia","is_ca":false},{"name":"Peter Hillmen","is_ca":false},{"name":"Florence Cymbalista","is_ca":false},{"name":"Tait D. Shanafelt","is_ca":false},{"name":"Graeme Fraser","is_ca":true},{"name":"Simon Rule","is_ca":false},{"name":"Thomas J. Kipps","is_ca":false},{"name":"Steven Coutré","is_ca":false},{"name":"Marie‐Sarah Dilhuydy","is_ca":false},{"name":"Paula Cramer","is_ca":false},{"name":"Alessandra Tedeschi","is_ca":false},{"name":"Ulrich Jaeger","is_ca":false},{"name":"Martin Dreyling","is_ca":false},{"name":"John C. Byrd","is_ca":false},{"name":"Angela Howes","is_ca":false},{"name":"Michael M. Todd","is_ca":false},{"name":"Jessica Vermeulen","is_ca":false},{"name":"Danelle F. James","is_ca":false},{"name":"Fong Clow","is_ca":false},{"name":"Lori Styles","is_ca":false},{"name":"Rudy Valentino","is_ca":false},{"name":"Mark Wildgust","is_ca":false},{"name":"Michelle Mahler","is_ca":false},{"name":"Jan A. Burger","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08473874912293827,"gpt":0.384229192574077,"spread":0.2994904434511387,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.1330268,0.001673532,0.007429526,0.006111081,0.0008610959,0.004314018,0.002430529,0.002611377,0.005494921],"category_scores_gemma":[0.2049791,0.0009480985,0.01263001,0.009576873,0.001296756,0.003003689,0.002247817,0.003568306,0.0006337641],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00153486,"about_ca_system_score_gemma":0.002030179,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006469387,"about_ca_topic_score_gemma":0.001103541,"domain_scores_codex":[0.751538,0.1268788,0.0870923,0.0146389,0.01724454,0.002607523],"domain_scores_gemma":[0.7101967,0.1717722,0.09170375,0.01445732,0.01023153,0.001638543],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"observational","study_design_scores_codex":[0.2048741,0.0009127057,0.1584301,0.1408982,0.2867471,0.0009014295,0.0010937,0.004513875,0.002121215,0.006589123,0.02366571,0.1692528],"study_design_scores_gemma":[0.1659559,0.01629682,0.39477,0.03424706,0.2290767,0.004356586,0.0008928521,0.01412928,0.004242122,0.02385971,0.1112863,0.0008867027],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.3266259,0.4889215,0.04584148,0.005281412,0.003284367,0.0445476,0.05910684,0.001082506,0.0253084],"genre_scores_gemma":[0.8737006,0.03215867,0.01421486,0.004271043,0.001232375,0.04838104,0.02430354,0.000281096,0.001456923],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.1330268,"threshold_uncertainty_score":0.7035215,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2560708148","doi":"10.1016/s1470-2045(16)30632-5","title":"Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":236,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Royal Victoria Hospital; Dalhousie University","funders":"Pharmacyclics","keywords":"Rituximab; Medicine; Ibrutinib; Internal medicine; Population; Waldenstrom macroglobulinemia; Oncology; Lymphoma; Leukemia; Chronic lymphocytic leukemia","authors":[{"name":"Meletios Α. Dimopoulos","is_ca":false},{"name":"Judith Trotman","is_ca":false},{"name":"Alessandra Tedeschi","is_ca":false},{"name":"Jeffrey V Matous","is_ca":false},{"name":"David Macdonald","is_ca":true},{"name":"Constantine S. Tam","is_ca":false},{"name":"Olivier Tournilhac","is_ca":false},{"name":"Shuo Ma","is_ca":false},{"name":"Albert Oriol","is_ca":false},{"name":"Leonard T. Heffner","is_ca":false},{"name":"Chaim Shustik","is_ca":true},{"name":"Ramón García‐Sánz","is_ca":false},{"name":"Robert F. Cornell","is_ca":false},{"name":"Carlos Fernández de Larrea","is_ca":false},{"name":"Jorge J. Castillo","is_ca":false},{"name":"Miquel Granell","is_ca":false},{"name":"Marie‐Christine Kyrtsonis","is_ca":false},{"name":"Véronique Leblond","is_ca":false},{"name":"Argiris Symeonidis","is_ca":false},{"name":"Efstathios Kastritis","is_ca":false},{"name":"Priyanka Singh","is_ca":false},{"name":"Jianling Li","is_ca":false},{"name":"Thorsten Graef","is_ca":false},{"name":"Elizabeth Bilotti","is_ca":false},{"name":"Steven P. Treon","is_ca":false},{"name":"Christian Buske","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1097531342863321,"gpt":0.454956165901559,"spread":0.3452030316152269,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003092271,0.001172639,0.002107235,0.0003743568,0.0003538103,0.001560047,0.0008498051,0.001313397,0.002296922],"category_scores_gemma":[0.001668175,0.000462825,0.002352491,0.0004735132,0.0008758156,0.001303175,0.0004639483,0.003300844,0.0007175041],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001078582,"about_ca_system_score_gemma":0.0008352181,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001059187,"about_ca_topic_score_gemma":0.003748472,"domain_scores_codex":[0.9992636,0.0003407871,0.00004153205,0.000108245,0.00007417996,0.0001715889],"domain_scores_gemma":[0.9992492,0.0002313537,0.0001901716,0.00007371247,0.00005015897,0.0002054471],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8413655,0.004445545,0.006743586,0.002180753,0.006531575,0.0001557083,0.0003621824,0.001495164,0.008476986,0.0004310241,0.005388552,0.1224235],"study_design_scores_gemma":[0.9250557,0.05018561,0.01308796,0.0002275516,0.003145802,0.0002211829,0.000134166,0.0006978548,0.001041507,0.0003994657,0.005754333,0.00004870007],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9598201,0.03080984,0.0005115864,0.001432638,0.0004485945,0.0009370641,0.001646505,0.0001274002,0.0042662],"genre_scores_gemma":[0.9823661,0.008863734,0.001095034,0.001972601,0.0003378785,0.0007442234,0.002710231,0.00003159866,0.001878626],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003092271,"threshold_uncertainty_score":0.01635373,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2041313070","doi":"10.1016/s1535-6108(03)00136-3","title":"Escape from Cbl-mediated downregulation","year":2003,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":234,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Receptor tyrosine kinase; Endocytosis; Downregulation and upregulation; Ubiquitin; Cell biology; Biology; Receptor; Lysosome; Signal transduction; Cancer research; Genetics; Biochemistry; Gene","authors":[{"name":"Pascal Peschard","is_ca":true},{"name":"Morag Park","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01826539337311441,"gpt":0.2899037747678703,"spread":0.2716383813947559,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002684734,0.0003499179,0.0003554432,0.0003185148,0.00027248,0.001204246,0.0004220848,0.0003975402,0.004704555],"category_scores_gemma":[0.0003505723,0.0001543671,0.0003733145,0.0001850009,0.0003116629,0.0003680307,0.0005813866,0.001575507,0.001922372],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007377273,"about_ca_system_score_gemma":0.0003912197,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008332485,"about_ca_topic_score_gemma":0.001217271,"domain_scores_codex":[0.999711,0.000029435,0.00001479807,0.00003824606,0.00008522005,0.0001212811],"domain_scores_gemma":[0.9997959,0.00004731328,0.00002398162,0.00006206191,0.00003616557,0.00003470426],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001097392,0.00004780859,0.0005178783,0.00003999997,0.00001090149,0.0002075592,0.00003302131,0.00007063934,0.9886118,0.00239574,0.0006829846,0.007271901],"study_design_scores_gemma":[0.00004354968,0.0001777211,0.00822185,0.0000163104,0.00001794904,0.001446606,0.00008035889,0.00093158,0.9700347,0.0006371104,0.01838377,0.000008533377],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9568055,0.004230976,0.008120816,0.001226377,0.0001910493,0.00006139348,0.001074333,0.0008218497,0.02746767],"genre_scores_gemma":[0.9852043,0.000459987,0.001083976,0.0002481768,0.00002363662,0.00003052241,0.0006208241,0.00007105993,0.01225746],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004704555,"threshold_uncertainty_score":0.01573831,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3088078660","doi":"10.1200/jco.20.00948","title":"Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":220,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; Jewish General Hospital","funders":"National Cancer Institute; University of California, San Diego; University of Texas MD Anderson Cancer Center; National Institutes of Health; Apellis Pharmaceuticals; BeiGene; National Comprehensive Cancer Network; University of Nebraska Medical Center; Universiteit van Amsterdam; Leukemia and Lymphoma Society; Alexion Pharmaceuticals; Gilead Sciences; Teva Pharmaceutical Industries; MorphoSys; Celgene; Pharmacyclics; Genentech; California Institute for Regenerative Medicine; AstraZeneca; Loxo Oncology; TG Therapeutics; Amgen; Breast Cancer Research Foundation","keywords":"Medicine; Venetoclax; Internal medicine; Bendamustine; Rituximab; Chronic lymphocytic leukemia; Regimen; Hazard ratio; Oncology; Progression-free survival; Gastroenterology; Alemtuzumab; Minimal residual disease; Leukemia; Chemotherapy; Lymphoma; Confidence interval; Transplantation","authors":[{"name":"Arnon P. Kater","is_ca":false},{"name":"Jenny Wu","is_ca":false},{"name":"Thomas J. Kipps","is_ca":false},{"name":"Barbara Eichhorst","is_ca":false},{"name":"Peter Hillmen","is_ca":false},{"name":"James D’Rozario","is_ca":false},{"name":"Sarit Assouline","is_ca":true},{"name":"Carolyn Owen","is_ca":true},{"name":"Tadeusz Robak","is_ca":false},{"name":"Javier de la Serna","is_ca":false},{"name":"Ulrich Jaeger","is_ca":false},{"name":"Guillaume Cartron","is_ca":false},{"name":"Marco Montillo","is_ca":false},{"name":"Julie Dubois","is_ca":false},{"name":"Eric Eldering","is_ca":false},{"name":"Clemens Mellink","is_ca":false},{"name":"Anne-Marie Van Der Kevie-Kersemaekers","is_ca":false},{"name":"Su Young Kim","is_ca":false},{"name":"Brenda Chyla","is_ca":false},{"name":"Elizabeth A. Punnoose","is_ca":false},{"name":"Christopher R. Bolen","is_ca":false},{"name":"Zoe J. Assaf","is_ca":false},{"name":"Yanwen Jiang","is_ca":false},{"name":"Jue Wang","is_ca":false},{"name":"Marcus Lefebure","is_ca":false},{"name":"Michelle Boyer","is_ca":false},{"name":"Kathryn Humphrey","is_ca":false},{"name":"John F. Seymour","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2785272315645372,"gpt":0.5228803570445849,"spread":0.2443531254800477,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004577626,0.0004829807,0.001321966,0.0003213171,0.000221828,0.0005760616,0.00051954,0.0006181948,0.0007091512],"category_scores_gemma":[0.002195984,0.0002047904,0.001167918,0.0003180999,0.0004591282,0.0003288168,0.0002722026,0.000965261,0.0001517076],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006839253,"about_ca_system_score_gemma":0.0005112542,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008988248,"about_ca_topic_score_gemma":0.001889635,"domain_scores_codex":[0.9984156,0.001131788,0.00006396906,0.0001241238,0.0001515204,0.0001131017],"domain_scores_gemma":[0.9978476,0.0007717267,0.0006449831,0.0002571852,0.00009417833,0.0003843174],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6871876,0.01073177,0.09995686,0.0006888366,0.004143749,0.0002182266,0.0002913422,0.002573164,0.01467487,0.0001758728,0.001376982,0.1779808],"study_design_scores_gemma":[0.1708218,0.4711107,0.3434008,0.0001564381,0.003434547,0.0005577814,0.000108299,0.002379932,0.003181791,0.0002750204,0.004512563,0.00006043333],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948304,0.004101959,0.0001228444,0.00008325763,0.00002362631,0.0001377504,0.0001925899,0.000008560557,0.0004990918],"genre_scores_gemma":[0.9970332,0.001208156,0.0003012292,0.0001982003,0.00007273443,0.000150871,0.0005964203,0.000005000292,0.0004342246],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004577626,"threshold_uncertainty_score":0.02420908,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2108305936","doi":"10.1038/ng.2652","title":"Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia","year":2013,"lang":"en","type":"review","venue":"Nature Genetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":211,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Simon Fraser University; BC Cancer Agency","funders":"National Institute of Environmental Health Sciences; National Cancer Institute; National Human Genome Research Institute; National Institutes of Health","keywords":"Chronic lymphocytic leukemia; Genome-wide association study; Biology; Single-nucleotide polymorphism; Locus (genetics); Genetics; Genetic association; Leukemia; Gene; Genotype","authors":[{"name":"Sonja I. Berndt","is_ca":false},{"name":"Christine F. Skibola","is_ca":false},{"name":"Joseph Vijai","is_ca":false},{"name":"Nicola J. Camp","is_ca":false},{"name":"Alexandra Nieters","is_ca":false},{"name":"Zhaoming Wang","is_ca":false},{"name":"Wendy Cozen","is_ca":false},{"name":"Alain Monnereau","is_ca":false},{"name":"Sophia Wang","is_ca":false},{"name":"Rachel S. Kelly","is_ca":false},{"name":"Qing Lan","is_ca":false},{"name":"Lauren R. Teras","is_ca":false},{"name":"Nilanjan Chatterjee","is_ca":false},{"name":"Charles C. Chung","is_ca":false},{"name":"Meredith Yeager","is_ca":false},{"name":"Angela Brooks‐Wilson","is_ca":true},{"name":"Patricia Hartge","is_ca":false},{"name":"Mark P. Purdue","is_ca":false},{"name":"Brenda M. Birmann","is_ca":false},{"name":"Bruce K. Armstrong","is_ca":false},{"name":"Pierluigi Cocco","is_ca":false},{"name":"Yawei Zhang","is_ca":false},{"name":"Gianluca Severi","is_ca":false},{"name":"Anne Zeleniuch‐Jacquotte","is_ca":false},{"name":"Charles Lawrence","is_ca":false},{"name":"Laurie Burdette","is_ca":false},{"name":"Jeffrey Yuenger","is_ca":false},{"name":"Amy Hutchinson","is_ca":false},{"name":"Kevin B. Jacobs","is_ca":false},{"name":"Timothy G. Call","is_ca":false},{"name":"Tait D. Shanafelt","is_ca":false},{"name":"Anne J. Novak","is_ca":false},{"name":"Neil E. Kay","is_ca":false},{"name":"Mark Liebow","is_ca":false},{"name":"Alice H. Wang","is_ca":false},{"name":"Karin E. Smedby","is_ca":false},{"name":"Hans‐Olov Adami","is_ca":false},{"name":"Mads Melbye","is_ca":false},{"name":"Bengt Glimelius","is_ca":false},{"name":"Ellen T. Chang","is_ca":false},{"name":"Martha Glenn","is_ca":false},{"name":"Karen Curtin","is_ca":false},{"name":"Lisa Cannon‐Albright","is_ca":false},{"name":"Brandt Jones","is_ca":false},{"name":"W. Ryan Diver","is_ca":false},{"name":"Brian K. Link","is_ca":false},{"name":"George J. Weiner","is_ca":false},{"name":"Lucía Conde","is_ca":false},{"name":"Paige M. Bracci","is_ca":false},{"name":"Jacques Riby","is_ca":false},{"name":"Elizabeth A. Holly","is_ca":false},{"name":"Martyn T. Smith","is_ca":false},{"name":"Rebecca D. Jackson","is_ca":false},{"name":"Lesley F. Tinker","is_ca":false},{"name":"Yolanda Benavente","is_ca":false},{"name":"Nikolaus Becker","is_ca":false},{"name":"Paolo Boffetta","is_ca":false},{"name":"Paul Brennan","is_ca":false},{"name":"Lenka Foretová","is_ca":false},{"name":"Marc Maynadié","is_ca":false},{"name":"James McKay","is_ca":false},{"name":"Anthony Staines","is_ca":false},{"name":"Kari G. Rabe","is_ca":false},{"name":"Sara J. Achenbach","is_ca":false},{"name":"Celine M. Vachon","is_ca":false},{"name":"Lynn R. Goldin","is_ca":false},{"name":"Sara S. Strom","is_ca":false},{"name":"Mark C. Lanasa","is_ca":false},{"name":"Logan G. Spector","is_ca":false},{"name":"José F. Leis","is_ca":false},{"name":"Julie M. Cunningham","is_ca":false},{"name":"J. Brice Weinberg","is_ca":false},{"name":"Vicki A. Morrison","is_ca":false},{"name":"Neil E. Caporaso","is_ca":false},{"name":"Aaron D. Norman","is_ca":false},{"name":"Martha S. Linet","is_ca":false},{"name":"Anneclaire J. De Roos","is_ca":false},{"name":"Lindsay M. Morton","is_ca":false},{"name":"Richard K. Severson","is_ca":false},{"name":"Elio Ríboli","is_ca":false},{"name":"Paolo Vineis","is_ca":false},{"name":"Rudolph Kaaks","is_ca":false},{"name":"Dimitrios Trichopoulos","is_ca":false},{"name":"Giovanna Masala","is_ca":false},{"name":"Elisabete Weiderpass","is_ca":false},{"name":"María‐Dolores Chirlaque","is_ca":false},{"name":"Roel Vermeulen","is_ca":false},{"name":"Ruth C. Travis","is_ca":false},{"name":"Graham G. Giles","is_ca":false},{"name":"Demetrius Albanes","is_ca":false},{"name":"Jarmo Virtamo","is_ca":false},{"name":"Stephanie J. Weinstein","is_ca":false},{"name":"Jacqueline Clavel","is_ca":false},{"name":"Tongzhang Zheng","is_ca":false},{"name":"Theodore R. Holford","is_ca":false},{"name":"Kenneth Offit","is_ca":false},{"name":"Andrew D. Zelenetz","is_ca":false},{"name":"Robert J. Klein","is_ca":false},{"name":"John J. Spinelli","is_ca":true},{"name":"Kimberly A. Bertrand","is_ca":false},{"name":"Francine Laden","is_ca":false},{"name":"Edward Giovannucci","is_ca":false},{"name":"Peter Kraft","is_ca":false},{"name":"Anne Kricker","is_ca":false},{"name":"Jennifer Turner","is_ca":false},{"name":"Claire M. Vajdic","is_ca":false},{"name":"Maria Grazia Ennas","is_ca":false},{"name":"Giovanni Maria Ferri","is_ca":false},{"name":"Lucia Miligi","is_ca":false},{"name":"Liming Liang","is_ca":false},{"name":"Joshua N. Sampson","is_ca":false},{"name":"Simon Crouch","is_ca":false},{"name":"Ju‐Hyun Park","is_ca":false},{"name":"Kari E. North","is_ca":false},{"name":"Angela Cox","is_ca":false},{"name":"John A. Snowden","is_ca":false},{"name":"Josh Wright","is_ca":false},{"name":"Ángel Carracedo","is_ca":false},{"name":"Carlos López-Otı́n","is_ca":false},{"name":"Sı́lvia Beà","is_ca":false},{"name":"Itziar Salaverría","is_ca":false},{"name":"David Martin‐García","is_ca":false},{"name":"Elı́as Campo","is_ca":false},{"name":"Joseph F. Fraumeni","is_ca":false},{"name":"Sílvia de Sanjosé","is_ca":false},{"name":"Henrik Hjalgrim","is_ca":false},{"name":"James R. Cerhan","is_ca":false},{"name":"Stephen J. Chanock","is_ca":false},{"name":"Nathaniel Rothman","is_ca":false},{"name":"Susan L. Slager","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03042199855255026,"gpt":0.3507989593304683,"spread":0.3203769607779181,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001513694,0.0009974916,0.001890531,0.002015556,0.0002468927,0.0008695559,0.0013143,0.001423855,0.002028533],"category_scores_gemma":[0.002040429,0.0003332486,0.0006559669,0.002496503,0.0006748526,0.0008525915,0.0008571429,0.001929568,0.001022791],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007198083,"about_ca_system_score_gemma":0.00157205,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002042791,"about_ca_topic_score_gemma":0.004363559,"domain_scores_codex":[0.9996069,0.00007536531,0.00006451269,0.00009083694,0.0001329991,0.00002946736],"domain_scores_gemma":[0.998624,0.0007854159,0.0001622338,0.0000361062,0.0002893976,0.0001028857],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.0001841642,0.00004624546,0.001519081,0.008485214,0.0003222924,0.0002672155,0.00002766809,0.0002049082,0.0008651707,0.001852524,0.04552591,0.9406996],"study_design_scores_gemma":[0.000127074,0.0001158683,0.008321336,0.006587598,0.001095199,0.001718625,0.0001046083,0.0001519962,0.0004809683,0.005067315,0.9761658,0.000063524],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00009484505,0.9983188,0.0001544708,0.0007540366,0.000239476,0.00000289994,0.00003387237,0.000007500224,0.0003941906],"genre_scores_gemma":[0.0007444141,0.9976779,0.0002353132,0.0005699329,0.0004615558,0.000005515706,0.00005839394,0.000001515856,0.00024551],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002042791,"threshold_uncertainty_score":0.008005261,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2589157782","doi":"10.1182/blood-2016-10-742437","title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","year":2017,"lang":"en","type":"letter","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; CancerCare Manitoba","funders":"National Cancer Institute","keywords":"Ibrutinib; Medicine; Bruton's tyrosine kinase; Food and drug administration; Internal medicine; Cardiology; Ventricular fibrillation; Tyrosine kinase; Pharmacology; Leukemia; Receptor","authors":[{"name":"Benjamin L. Lampson","is_ca":false},{"name":"Lijian Yu","is_ca":false},{"name":"Robert J. Glynn","is_ca":false},{"name":"Jacqueline C. Barrientos","is_ca":false},{"name":"Eric D. Jacobsen","is_ca":false},{"name":"Versha Banerji","is_ca":true},{"name":"Jeffrey A. Jones","is_ca":false},{"name":"Renata Walewska","is_ca":false},{"name":"Kerry J. Savage","is_ca":true},{"name":"Gregory F. Michaud","is_ca":false},{"name":"Javid J. Moslehi","is_ca":false},{"name":"Jennifer R. Brown","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0279046217906631,"gpt":0.291713119591134,"spread":0.2638084978004709,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009077295,0.0004666777,0.0008997858,0.0008021199,0.001351823,0.001381023,0.000857904,0.009738983,0.003709714],"category_scores_gemma":[0.008655455,0.0003771704,0.0006046881,0.0008704387,0.0008874375,0.001557346,0.0004473342,0.008984596,0.001906943],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001228981,"about_ca_system_score_gemma":0.0008693628,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001136378,"about_ca_topic_score_gemma":0.002289816,"domain_scores_codex":[0.9992982,0.0002072134,0.0001068501,0.0001294288,0.0001510682,0.0001072442],"domain_scores_gemma":[0.9972872,0.001361697,0.0003477628,0.00008318209,0.000441825,0.0004784018],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"case_report","study_design_scores_codex":[0.0006889154,0.0002898247,0.0569653,0.0003619323,0.0001931324,0.1941905,0.0008063572,0.0002715151,0.001060194,0.002602097,0.6899601,0.05261015],"study_design_scores_gemma":[0.001400076,0.001031166,0.09244061,0.003100394,0.0006738833,0.4572338,0.003557302,0.004423305,0.001237724,0.02015258,0.4143954,0.0003536905],"study_design_candidate":"case_report","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.02818326,0.01052574,0.0003284012,0.919374,0.02649276,0.00004443072,0.0002159829,0.00008651639,0.01474905],"genre_scores_gemma":[0.2332633,0.01178339,0.0007007791,0.5170456,0.2281483,0.0000784587,0.0002245229,0.00004515862,0.008710391],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.009738983,"threshold_uncertainty_score":0.01241022,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4205825534","doi":"10.1038/s41375-021-01485-x","title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia","year":2022,"lang":"en","type":"letter","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"AstraZeneca","keywords":"Obinutuzumab; Chlorambucil; Chronic lymphocytic leukemia; Medicine; Ibrutinib; Internal medicine; Bruton's tyrosine kinase; Oncology; Clinical endpoint; Leukemia; Clinical trial; Chemotherapy; Tyrosine kinase; Cyclophosphamide","authors":[{"name":"Jeff P. Sharman","is_ca":false},{"name":"Miklós Egyed","is_ca":false},{"name":"Wojciech Jurczak","is_ca":false},{"name":"Alan P Skarbnik","is_ca":false},{"name":"John M. Pagel","is_ca":false},{"name":"Ian W. Flinn","is_ca":false},{"name":"Manali Kamdar","is_ca":false},{"name":"Talha Munir","is_ca":false},{"name":"Renata Walewska","is_ca":false},{"name":"Gillian Corbett","is_ca":false},{"name":"Laura Fogliatto","is_ca":false},{"name":"Yair Herishanu","is_ca":false},{"name":"Versha Banerji","is_ca":true},{"name":"Steven Coutré","is_ca":false},{"name":"George Follows","is_ca":false},{"name":"Patricia Walker","is_ca":false},{"name":"Karin Karlsson","is_ca":false},{"name":"Paolo Ghia","is_ca":false},{"name":"Ann Janssens","is_ca":false},{"name":"Florence Cymbalista","is_ca":false},{"name":"Jennifer A. Woyach","is_ca":false},{"name":"Emmanuelle Ferrant","is_ca":false},{"name":"William G. Wierda","is_ca":false},{"name":"Veerendra Munugalavadla","is_ca":false},{"name":"Ting Yu","is_ca":false},{"name":"Min Hui Wang","is_ca":false},{"name":"John C. Byrd","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04697134715739797,"gpt":0.3070144821862215,"spread":0.2600431350288235,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003454093,0.0004221469,0.001521543,0.0002635319,0.0005569739,0.001340415,0.0005175634,0.004162434,0.002142034],"category_scores_gemma":[0.006745127,0.0002864103,0.001798444,0.0005490507,0.0004692817,0.00084812,0.00025395,0.003163834,0.0007519442],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001709801,"about_ca_system_score_gemma":0.0007977841,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001809944,"about_ca_topic_score_gemma":0.002411537,"domain_scores_codex":[0.9983725,0.0007230399,0.0001831408,0.0002418598,0.0002671577,0.0002122962],"domain_scores_gemma":[0.9945307,0.002947218,0.0008734229,0.0002930937,0.0005318738,0.0008236975],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4043885,0.01065897,0.2560751,0.0006539388,0.005722981,0.01295433,0.0007847228,0.003560563,0.01098227,0.001048804,0.07084247,0.2223274],"study_design_scores_gemma":[0.1332829,0.1519424,0.5981748,0.0003878596,0.00979769,0.01655634,0.0005189318,0.009719057,0.006933355,0.004598135,0.0677738,0.0003146346],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9305052,0.01124194,0.0006632783,0.0384922,0.001542143,0.0003144018,0.00485803,0.00006976349,0.01231301],"genre_scores_gemma":[0.9548348,0.001635737,0.0005570792,0.03217192,0.001965035,0.0001938767,0.003029093,0.00002247084,0.005589914],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004162434,"threshold_uncertainty_score":0.01826721,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2594646846","doi":"10.1016/s2352-3026(17)30019-4","title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":198,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Alberta Health Services","funders":"Gilead Sciences; Lymphoma Research Foundation","keywords":"Ofatumumab; Idelalisib; Medicine; Internal medicine; Population; IGHV@; Clinical endpoint; Chronic lymphocytic leukemia; Ibrutinib; Rituximab; Clinical trial; Oncology; Gastroenterology; Lymphoma; Leukemia","authors":[{"name":"Jeffrey A. Jones","is_ca":false},{"name":"Tadeusz Robak","is_ca":false},{"name":"Jennifer R. Brown","is_ca":false},{"name":"Farrukh T. Awan","is_ca":false},{"name":"Xavier C. Badoux","is_ca":false},{"name":"Steven Coutré","is_ca":false},{"name":"Javier Loscertales","is_ca":false},{"name":"Kerry Taylor","is_ca":false},{"name":"Elisabeth Vandenberghe","is_ca":false},{"name":"Małgorzata Wach","is_ca":false},{"name":"Nina D. Wagner‐Johnston","is_ca":false},{"name":"Loïc Ysebaert","is_ca":false},{"name":"Lyndah Dreiling","is_ca":false},{"name":"Ronald L. Dubowy","is_ca":false},{"name":"Guan Xing","is_ca":false},{"name":"Ian W. Flinn","is_ca":false},{"name":"Carolyn Owen","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09379685803426602,"gpt":0.4174588566744332,"spread":0.3236619986401672,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002577946,0.002494402,0.004611185,0.0005781699,0.0006681593,0.001970759,0.001223698,0.00262363,0.005617452],"category_scores_gemma":[0.001927524,0.001004303,0.003419393,0.0005901035,0.002107101,0.00225697,0.0005909182,0.005190067,0.001631327],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00158999,"about_ca_system_score_gemma":0.001170734,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001253291,"about_ca_topic_score_gemma":0.002432638,"domain_scores_codex":[0.9989452,0.0005341771,0.0000576335,0.0001837148,0.00007811447,0.0002011729],"domain_scores_gemma":[0.9987934,0.0003331969,0.0002523516,0.0001126734,0.00006107748,0.0004473242],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9810281,0.003141744,0.0005874559,0.0003644333,0.00115085,0.00004904908,0.00004981612,0.0002959302,0.001806335,0.00007515772,0.0005856184,0.01086535],"study_design_scores_gemma":[0.946014,0.05106906,0.001315894,0.00002499535,0.0004462846,0.00004751973,0.00001944554,0.0002486877,0.0001843417,0.0001178666,0.0004949644,0.00001692556],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9872425,0.006819674,0.000490904,0.0007230265,0.0006446709,0.00146378,0.0008016573,0.0001046441,0.00170924],"genre_scores_gemma":[0.9888263,0.002718147,0.0009707826,0.001135321,0.0004801356,0.002078755,0.001403422,0.00003472808,0.002352508],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005617452,"threshold_uncertainty_score":0.01879221,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2160542415","doi":"10.1200/jco.2006.07.8659","title":"Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":189,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Bortezomib; Neutropenia; Internal medicine; Gastroenterology; Macroglobulinemia; Waldenstrom macroglobulinemia; Discontinuation; Toxicity; Peripheral neuropathy; Cancer; Surgery; Multiple myeloma; Lymphoma","authors":[{"name":"Christine I. Chen","is_ca":true},{"name":"C. Tom Kouroukis","is_ca":true},{"name":"Darrell White","is_ca":true},{"name":"Michael Voralia","is_ca":true},{"name":"Edward A. Stadtmauer","is_ca":true},{"name":"A. Keith Stewart","is_ca":true},{"name":"Jean Powers","is_ca":true},{"name":"Wendy Walsh","is_ca":true},{"name":"Elizabeth A. Eisenhauer","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.212617650926609,"gpt":0.5550014234986691,"spread":0.3423837725720601,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001993768,0.0008488261,0.001558801,0.0002651784,0.0005239063,0.0006467944,0.0005408234,0.0007041002,0.001307729],"category_scores_gemma":[0.0008048195,0.0003856356,0.0006118938,0.0004616072,0.0007112164,0.0003122628,0.0001719099,0.001265862,0.0002633176],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001681409,"about_ca_system_score_gemma":0.003080289,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009092648,"about_ca_topic_score_gemma":0.0364663,"domain_scores_codex":[0.999512,0.0002169399,0.00002683421,0.00005331614,0.00008910483,0.0001018065],"domain_scores_gemma":[0.9993275,0.00009377699,0.0001399233,0.00002707255,0.00005546093,0.0003562007],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5687774,0.04153895,0.13436,0.001861966,0.003184626,0.0009628221,0.0005880845,0.002616,0.05046426,0.0003713446,0.01113237,0.1841421],"study_design_scores_gemma":[0.5455219,0.2247206,0.2113467,0.0001334291,0.001102135,0.001005476,0.0001242506,0.00150928,0.003094839,0.0001392014,0.01125205,0.00005008845],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899094,0.006859769,0.0001472129,0.0004904922,0.00006127219,0.0009144248,0.000581889,0.00002337245,0.001012282],"genre_scores_gemma":[0.9896079,0.004237486,0.0008460609,0.001009541,0.0001926719,0.0009063989,0.002234273,0.000009443797,0.0009562758],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009092648,"threshold_uncertainty_score":0.01807946,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3170908410","doi":"10.1158/2159-8290.cd-21-0145","title":"Enhancer Hijacking Drives Oncogenic <i>BCL11B</i> Expression in Lineage-Ambiguous Stem Cell Leukemia","year":2021,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":188,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"National Institute of General Medical Sciences; Canadian Institutes of Health Research; National Cancer Institute; Ontario Institute for Cancer Research; National Institutes of Health; Canadian Cancer Society; Damon Runyon Cancer Research Foundation","keywords":"Enhancer; Stem cell; Biology; Cancer research; Leukemia; Lineage (genetic); Cell biology; Gene; Genetics; Gene expression","authors":[{"name":"Lindsey E. Montefiori","is_ca":false},{"name":"Sonja Bendig","is_ca":false},{"name":"Zhaohui Gu","is_ca":false},{"name":"Xiaolong Chen","is_ca":false},{"name":"Petri Pölönen","is_ca":false},{"name":"Xiaotu Ma","is_ca":false},{"name":"Alex Murison","is_ca":true},{"name":"Andy G.X. Zeng","is_ca":true},{"name":"Laura García‐Prat","is_ca":true},{"name":"Kirsten Dickerson","is_ca":false},{"name":"Ilaria Iacobucci","is_ca":false},{"name":"Sherif Abdelhamed","is_ca":false},{"name":"Ryan Hiltenbrand","is_ca":false},{"name":"Paul E. Mead","is_ca":false},{"name":"Cyrus M. Mehr","is_ca":false},{"name":"Beisi Xu","is_ca":false},{"name":"Zhongshan Cheng","is_ca":false},{"name":"Ti‐Cheng Chang","is_ca":false},{"name":"Tamara Westover","is_ca":false},{"name":"Jing Ma","is_ca":false},{"name":"Anna Stengel","is_ca":false},{"name":"Shunsuke Kimura","is_ca":false},{"name":"Chunxu Qu","is_ca":false},{"name":"Marcus B. Valentine","is_ca":false},{"name":"Marissa Rashkovan","is_ca":false},{"name":"Selina M. Luger","is_ca":false},{"name":"Mark R. Litzow","is_ca":false},{"name":"Jacob M. Rowe","is_ca":false},{"name":"Monique L. den Boer","is_ca":false},{"name":"Victoria Wang","is_ca":false},{"name":"Jun Yin","is_ca":false},{"name":"Steven M. Kornblau","is_ca":false},{"name":"Stephen P. Hunger","is_ca":false},{"name":"Mignon L. Loh","is_ca":false},{"name":"Ching‐Hon Pui","is_ca":false},{"name":"Wenjian Yang","is_ca":false},{"name":"Kristine R. Crews","is_ca":false},{"name":"Kathryn G. Roberts","is_ca":false},{"name":"Jun J. Yang","is_ca":false},{"name":"Mary V. Relling","is_ca":false},{"name":"William E. Evans","is_ca":false},{"name":"Wendy Stock","is_ca":false},{"name":"Elisabeth Paietta","is_ca":false},{"name":"Adolfo A. Ferrando","is_ca":false},{"name":"Jinghui Zhang","is_ca":false},{"name":"Wolfgang Kern","is_ca":false},{"name":"Torsten Haferlach","is_ca":false},{"name":"Gang Wu","is_ca":false},{"name":"John E. Dick","is_ca":true},{"name":"Jeffery M. Klco","is_ca":false},{"name":"Claudia Haferlach","is_ca":false},{"name":"Charles G. Mullighan","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02139903256790399,"gpt":0.3059097712941333,"spread":0.2845107387262293,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006556491,0.000129201,0.00007596848,0.0001317684,0.0001297446,0.0003666125,0.000130204,0.0001978496,0.001840546],"category_scores_gemma":[0.00007642181,0.00008630355,0.00006203511,0.0001001325,0.0002682196,0.0001222352,0.0002761829,0.0005462129,0.000543521],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002705204,"about_ca_system_score_gemma":0.0001361391,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003467648,"about_ca_topic_score_gemma":0.0005347963,"domain_scores_codex":[0.9999154,0.000008730414,0.000007120829,0.00001574727,0.00002780899,0.00002517254],"domain_scores_gemma":[0.9999381,0.0000117812,0.00002041079,0.000006660041,0.00000358625,0.00001946939],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00008120121,0.00002132991,0.001485887,0.00001738261,0.000002501965,0.0003385091,0.00001953308,0.000104695,0.9946583,0.0006324075,0.0002386561,0.002399605],"study_design_scores_gemma":[0.00001793313,0.0001274249,0.02272571,0.000007134801,0.00001239663,0.003211586,0.0001193598,0.002745416,0.9617482,0.0003917035,0.008887199,0.000006041758],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9929721,0.0006785913,0.002878395,0.0001781251,0.00003052349,0.00001699241,0.0003048403,0.0001852487,0.002755227],"genre_scores_gemma":[0.9972245,0.0002994172,0.000607301,0.00005489048,0.000009843,0.000006541812,0.0002822569,0.00001723331,0.00149813],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001840546,"threshold_uncertainty_score":0.006157219,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2115093629","doi":"10.1038/leu.2012.257","title":"IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas","year":2012,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":174,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Institute of Cancer Research; Institut Bergonié; Institut National Du Cancer; Ligue Contre le Cancer","keywords":"IGHV@; Biology; Waldenstrom macroglobulinemia; Lymphoplasmacytic Lymphoma; Macroglobulinemia; Immunoglobulin heavy chain; Lymphoma; Gene rearrangement; Antibody; Cancer research; Gene; Immunology; Genetics; Chronic lymphocytic leukemia; Leukemia; Multiple myeloma","authors":[{"name":"Nathalie Gachard","is_ca":false},{"name":"Marie Parrens","is_ca":false},{"name":"Isabelle Soubeyran","is_ca":false},{"name":"Barbara Petit","is_ca":false},{"name":"Abdelghafour Marfak","is_ca":false},{"name":"David Rizzo","is_ca":false},{"name":"Manuel Devesa","is_ca":false},{"name":"Manuela Delage-Corre","is_ca":false},{"name":"V. Coste","is_ca":false},{"name":"Marie‐Pierre Laforêt","is_ca":false},{"name":"A. de Mascarel","is_ca":false},{"name":"Jean‐Philippe Merlio","is_ca":false},{"name":"K Bouabdhalla","is_ca":false},{"name":"Nöel Milpied","is_ca":false},{"name":"Pierre Soubeyran","is_ca":false},{"name":"Anna Schmitt","is_ca":false},{"name":"Dominique Bordessoule","is_ca":false},{"name":"Michel Cogné","is_ca":false},{"name":"Jean Feuillard","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01437837057025398,"gpt":0.2692461794673759,"spread":0.254867808897122,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004764507,0.0007138423,0.000575283,0.001749867,0.0004620088,0.001460315,0.0009831027,0.001092914,0.002084749],"category_scores_gemma":[0.001434829,0.0003779635,0.0004149553,0.0006338635,0.001209455,0.0008538503,0.001046063,0.0007507238,0.0008624931],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004550961,"about_ca_system_score_gemma":0.000374176,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001059906,"about_ca_topic_score_gemma":0.001464168,"domain_scores_codex":[0.9996514,0.00004082842,0.00003909228,0.00004675487,0.00006646931,0.0001554269],"domain_scores_gemma":[0.9993529,0.0001347721,0.0001792475,0.00005948033,0.00004511912,0.0002284123],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002865606,0.0002882488,0.7238338,0.0001903201,0.0001154115,0.09874623,0.0009047443,0.0004636599,0.1390013,0.003637945,0.001114609,0.02883823],"study_design_scores_gemma":[0.0002605575,0.0006019638,0.6961212,0.00007214007,0.0001557618,0.2809796,0.001615845,0.002581436,0.01242156,0.00241167,0.002733547,0.00004471208],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941669,0.0006143761,0.0006438242,0.0001726908,0.00001677714,0.00003675853,0.00007167163,0.00004723289,0.00422975],"genre_scores_gemma":[0.999099,0.000114605,0.0004039039,0.00004786314,0.00003220101,0.000008665875,0.0001119539,0.000007867654,0.0001740388],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002084749,"threshold_uncertainty_score":0.00697422,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2606627097","doi":"10.1084/jem.20160894","title":"Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2","year":2017,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Hertz Foundation; National Institutes of Health; National Science Foundation","keywords":"KRAS; Cancer research; Lymphoma; Biology; Enteropathy; Mutation; T-cell lymphoma; Genetics; Gene; Medicine; Disease; Immunology; Internal medicine","authors":[{"name":"Andrea B. Moffitt","is_ca":false},{"name":"Sarah L. Ondrejka","is_ca":false},{"name":"Matthew McKinney","is_ca":false},{"name":"Rachel E. Rempel","is_ca":false},{"name":"John R. Goodlad","is_ca":false},{"name":"Chun Huat Teh","is_ca":false},{"name":"Sirpa Leppä","is_ca":false},{"name":"Susanna Mannisto","is_ca":false},{"name":"Panu E. Kovanen","is_ca":false},{"name":"Eric Tse","is_ca":false},{"name":"Rex Au-Yeung","is_ca":false},{"name":"Yok‐Lam Kwong","is_ca":false},{"name":"Gopesh Srivastava","is_ca":false},{"name":"Javeed Iqbal","is_ca":false},{"name":"Jiayu Yu","is_ca":false},{"name":"Kikkeri N. Naresh","is_ca":false},{"name":"Diego Villa","is_ca":true},{"name":"Randy D. Gascoyne","is_ca":true},{"name":"Jonathan Said","is_ca":false},{"name":"Magdalena Czader","is_ca":false},{"name":"Amy Chadburn","is_ca":false},{"name":"Kristy L. Richards","is_ca":false},{"name":"Deepthi Rajagopalan","is_ca":false},{"name":"Nicholas S. Davis","is_ca":false},{"name":"Eileen Smith","is_ca":false},{"name":"Brooke C. Palus","is_ca":false},{"name":"Tiffany J. Tzeng","is_ca":false},{"name":"Jane Healy","is_ca":false},{"name":"Patricia Lugar","is_ca":false},{"name":"Jyotishka Datta","is_ca":false},{"name":"Cassandra Love","is_ca":false},{"name":"Shawn Levy","is_ca":false},{"name":"David B. Dunson","is_ca":false},{"name":"Yuan Zhuang","is_ca":false},{"name":"Eric D. Hsi","is_ca":false},{"name":"Sandeep S. Davé","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02151496905255839,"gpt":0.3070130836189852,"spread":0.2854981145664268,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000871166,0.0002720384,0.0001947414,0.0005639545,0.0002126826,0.0003948599,0.0001505612,0.0001849555,0.001205999],"category_scores_gemma":[0.0002186447,0.0001058722,0.0002691536,0.0004810104,0.0002243963,0.0001277491,0.0002671502,0.0002484178,0.0002441132],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002346333,"about_ca_system_score_gemma":0.0001021983,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004555323,"about_ca_topic_score_gemma":0.001012651,"domain_scores_codex":[0.9998813,0.00001269067,0.0000150215,0.00003298711,0.00003241844,0.00002565939],"domain_scores_gemma":[0.9999051,0.00001534826,0.00003965526,0.00001115734,0.000008364887,0.00002031666],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001042141,0.00005691261,0.1744346,0.0001129662,0.0001152249,0.004046835,0.0001702061,0.0004154895,0.7973691,0.0005211341,0.0004902888,0.02122516],"study_design_scores_gemma":[0.0001829458,0.000419617,0.6886072,0.00005429416,0.000302861,0.06844359,0.000572104,0.003318217,0.2244083,0.001160038,0.01249862,0.00003232503],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967902,0.0004273782,0.0008884428,0.00003265206,0.000004618328,0.00001481143,0.0007006532,0.00002770379,0.001113556],"genre_scores_gemma":[0.9978817,0.0001974899,0.0004813595,0.00003469666,0.000003124603,0.000009471085,0.001018382,0.00001070162,0.0003632203],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001205999,"threshold_uncertainty_score":0.004034519,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2905558559","doi":"10.1182/blood-2018-07-862953","title":"Bruton tyrosine kinase degradation as a therapeutic strategy for cancer","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; National Institutes of Health; Harvard University; National Cancer Institute; Damon Runyon Cancer Research Foundation","keywords":"Bruton's tyrosine kinase; Ibrutinib; Mantle cell lymphoma; Cancer research; Tyrosine kinase; B cell; Lymphoma; Medicine; Biology; Immunology; Chronic lymphocytic leukemia; Signal transduction; Leukemia; Cell biology; Antibody","authors":[{"name":"Dennis Dobrovolsky","is_ca":false},{"name":"Eric S. Wang","is_ca":false},{"name":"Sara Morrow","is_ca":false},{"name":"Catharine Leahy","is_ca":false},{"name":"T.B. Faust","is_ca":false},{"name":"Radosław P. Nowak","is_ca":false},{"name":"Katherine A. Donovan","is_ca":false},{"name":"Guang Yang","is_ca":false},{"name":"Zhengnian Li","is_ca":false},{"name":"Eric S. Fischer","is_ca":false},{"name":"Steven P. Treon","is_ca":false},{"name":"David M. Weinstock","is_ca":false},{"name":"Nathanael S. Gray","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05432628899998896,"gpt":0.3694761640136313,"spread":0.3151498750136423,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001539396,0.0003171246,0.0002209076,0.0002232599,0.0001338851,0.0003320036,0.0001876578,0.000267379,0.0007865135],"category_scores_gemma":[0.00007420471,0.0001167661,0.0002085782,0.0001388399,0.0002520077,0.0002858483,0.0002719785,0.0005054696,0.0002247845],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003539985,"about_ca_system_score_gemma":0.0002624131,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003133251,"about_ca_topic_score_gemma":0.0006275579,"domain_scores_codex":[0.9999198,0.0000130704,0.000005384783,0.00001434386,0.00002116497,0.00002619192],"domain_scores_gemma":[0.999972,0.0000034548,0.000009110314,0.000003757567,0.000004022671,0.000007677524],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002410085,0.0001509365,0.0003941771,0.0002088213,0.00002105612,0.0002409706,0.00003824139,0.001235312,0.9625189,0.0020423,0.0006768726,0.03223145],"study_design_scores_gemma":[0.0001217316,0.001179696,0.0007905799,0.00001598435,0.00002924009,0.001133382,0.00002031769,0.001962399,0.9745482,0.0005085501,0.01967683,0.00001299809],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.926875,0.03601378,0.02332343,0.001458867,0.000202664,0.0002474714,0.0003140793,0.0004077881,0.01115698],"genre_scores_gemma":[0.9804889,0.009829871,0.005754008,0.000345944,0.00002855268,0.00004384916,0.0001912646,0.00001922295,0.003298418],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0007865135,"threshold_uncertainty_score":0.002631128,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1970006069","doi":"10.1038/ng.626","title":"Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32","year":2010,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; Simon Fraser University; BC Cancer Agency","funders":"National Institute of Environmental Health Sciences; National Cancer Institute","keywords":"Follicular lymphoma; Biology; Chronic lymphocytic leukemia; Lymphoma; Genome-wide association study; Genetic association; Locus (genetics); Genetics; Leukemia; Single-nucleotide polymorphism; Immunology; Gene; Genotype","authors":[{"name":"Lucía Conde","is_ca":false},{"name":"Eran Halperin","is_ca":false},{"name":"Nicholas K. Akers","is_ca":false},{"name":"Kevin M. Brown","is_ca":false},{"name":"Karin E. Smedby","is_ca":false},{"name":"Nathaniel Rothman","is_ca":false},{"name":"Alexandra Nieters","is_ca":false},{"name":"Susan L Slager","is_ca":false},{"name":"Angela Brooks‐Wilson","is_ca":true},{"name":"Luz Agana","is_ca":false},{"name":"Jacques Riby","is_ca":false},{"name":"Jianjun Liu","is_ca":false},{"name":"Hans‐Olov Adami","is_ca":false},{"name":"Hatef Darabi","is_ca":false},{"name":"Henrik Hjalgrim","is_ca":false},{"name":"Hui-Qi Low","is_ca":false},{"name":"Keith Humphreys","is_ca":false},{"name":"Mads Melbye","is_ca":false},{"name":"Ellen T. Chang","is_ca":false},{"name":"Bengt Glimelius","is_ca":false},{"name":"Wendy Cozen","is_ca":false},{"name":"S. Scott Davis","is_ca":false},{"name":"Patricia Hartge","is_ca":false},{"name":"Lindsay M. Morton","is_ca":false},{"name":"Maryjean Schenk","is_ca":false},{"name":"Sophia Wang","is_ca":false},{"name":"Bruce K. Armstrong","is_ca":false},{"name":"Anne Kricker","is_ca":false},{"name":"Sam Milliken","is_ca":false},{"name":"Mark P. Purdue","is_ca":false},{"name":"Claire M. Vajdic","is_ca":false},{"name":"Peter Boyle","is_ca":false},{"name":"Qing Lan","is_ca":false},{"name":"Shelia Hoar Zahm","is_ca":false},{"name":"Yawei Zhang","is_ca":false},{"name":"Tongzhang Zheng","is_ca":false},{"name":"Nikolaus Becker","is_ca":false},{"name":"Yolanda Benavente","is_ca":false},{"name":"Paolo Boffetta","is_ca":false},{"name":"Paul Brennan","is_ca":false},{"name":"Katja Butterbach","is_ca":false},{"name":"Pierluigi Cocco","is_ca":false},{"name":"Lenka Foretová","is_ca":false},{"name":"Marc Maynadié","is_ca":false},{"name":"Sílvia de Sanjosé","is_ca":false},{"name":"Anthony Staines","is_ca":false},{"name":"John J. Spinelli","is_ca":true},{"name":"Sara J. Achenbach","is_ca":false},{"name":"Timothy G. Call","is_ca":false},{"name":"Nicola J. Camp","is_ca":false},{"name":"Martha Glenn","is_ca":false},{"name":"Neil E. Caporaso","is_ca":false},{"name":"James R. Cerhan","is_ca":false},{"name":"Julie M. Cunningham","is_ca":false},{"name":"Lynn R. Goldin","is_ca":false},{"name":"Curtis A. Hanson","is_ca":false},{"name":"Neil E. Kay","is_ca":false},{"name":"Mark C. Lanasa","is_ca":false},{"name":"José F. Leis","is_ca":false},{"name":"Gerald E. Marti","is_ca":false},{"name":"Kari G. Rabe","is_ca":false},{"name":"Laura Z. Rassenti","is_ca":false},{"name":"Logan G. Spector","is_ca":false},{"name":"Sara S. Strom","is_ca":false},{"name":"Celine M. Vachon","is_ca":false},{"name":"J. Brice Weinberg","is_ca":false},{"name":"Elizabeth A. Holly","is_ca":false},{"name":"Stephen J. Chanock","is_ca":false},{"name":"Martyn T. Smith","is_ca":false},{"name":"Paige M. Bracci","is_ca":false},{"name":"Christine F. Skibola","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007304496344641298,"gpt":0.2810534068355785,"spread":0.2737489104909372,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006425781,0.0005450859,0.000373615,0.001359965,0.0005653891,0.0005558486,0.0005678196,0.0008780839,0.006079729],"category_scores_gemma":[0.002451221,0.0003048451,0.0006383589,0.001204952,0.000320823,0.0001928539,0.0005057539,0.0008224522,0.0006091723],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001828948,"about_ca_system_score_gemma":0.0002042978,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002608974,"about_ca_topic_score_gemma":0.002268054,"domain_scores_codex":[0.999469,0.0001903913,0.00003490271,0.000126403,0.0001129327,0.00006634781],"domain_scores_gemma":[0.9989113,0.0004312799,0.0002405745,0.0001095609,0.00008848705,0.0002189144],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007093378,0.0004817501,0.7480928,0.0001825716,0.001722358,0.007332749,0.0006368819,0.0005941464,0.1846891,0.0009713346,0.004927089,0.04327587],"study_design_scores_gemma":[0.0003462336,0.0005745686,0.9786844,0.00002777125,0.0007067989,0.007235053,0.0001700764,0.001029767,0.006848355,0.0007472457,0.00360481,0.00002497312],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946623,0.00110551,0.001454357,0.0005727495,0.00004144162,0.00002377102,0.0007394317,0.00007519383,0.001325115],"genre_scores_gemma":[0.9973602,0.0003024999,0.0007559884,0.00006424939,0.00004581164,0.00001776975,0.000516627,0.00001467759,0.0009221134],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006079729,"threshold_uncertainty_score":0.02033871,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2765414225","doi":"10.1182/blood-2017-09-804641","title":"Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Human Genome Research Institute","keywords":"Ibrutinib; Rituximab; Medicine; Follicular lymphoma; Oncology; Refractory (planetary science); Internal medicine; Idelalisib; Phases of clinical research; Clinical trial; Lymphoma; Leukemia; Chronic lymphocytic leukemia; Biology","authors":[{"name":"Nancy L. Bartlett","is_ca":false},{"name":"Brian A. Costello","is_ca":false},{"name":"Betsy LaPlant","is_ca":false},{"name":"Stephen M. Ansell","is_ca":false},{"name":"John Kuruvilla","is_ca":true},{"name":"Craig B. Reeder","is_ca":false},{"name":"Lim Soon Thye","is_ca":false},{"name":"Daniel M. Anderson","is_ca":false},{"name":"Kilannin Krysiak","is_ca":false},{"name":"Cody A. Ramirez","is_ca":false},{"name":"Jing Qi","is_ca":false},{"name":"Barry A. Siegel","is_ca":false},{"name":"Malachi Griffith","is_ca":false},{"name":"Obi L. Griffith","is_ca":false},{"name":"Felicia Gomez","is_ca":false},{"name":"Todd A. Fehniger","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06832704270368069,"gpt":0.3612379891516637,"spread":0.292910946447983,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003068795,0.001174839,0.001410967,0.0003167771,0.0004074532,0.001351096,0.0008433082,0.001538869,0.005469467],"category_scores_gemma":[0.001675493,0.0002925241,0.001207096,0.0004724791,0.0008172741,0.0009693003,0.0005097305,0.002846096,0.001477993],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001283365,"about_ca_system_score_gemma":0.001444821,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001013515,"about_ca_topic_score_gemma":0.002552227,"domain_scores_codex":[0.9992645,0.000406369,0.00003052919,0.0001039647,0.00007216931,0.0001224025],"domain_scores_gemma":[0.9990653,0.0001898273,0.000159843,0.0001127454,0.00007700691,0.0003952495],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7376468,0.02737816,0.007947723,0.001352138,0.003254291,0.0003295291,0.0003627834,0.002702932,0.01806004,0.0007390884,0.0140782,0.1861484],"study_design_scores_gemma":[0.8421467,0.1333494,0.01108149,0.0001585028,0.0009819228,0.0002905152,0.0001118076,0.001437232,0.001885134,0.0005853979,0.007922715,0.00004928969],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9797474,0.006780158,0.0005537475,0.002114288,0.0002676974,0.002624624,0.003096076,0.0001582368,0.004657809],"genre_scores_gemma":[0.9807652,0.002950635,0.001729407,0.002141341,0.0002836387,0.003475506,0.004434772,0.00004941869,0.004170194],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005469467,"threshold_uncertainty_score":0.0182972,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2072043914","doi":"10.1038/ng.419","title":"Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma","year":2009,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"National Institute of Environmental Health Sciences; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Follicular lymphoma; Chronic lymphocytic leukemia; Lymphoma; Biology; Follicular phase; Allele; Genetic association; Genome-wide association study; Leukemia; Genetics; Single-nucleotide polymorphism; Immunology; Gene; Genotype","authors":[{"name":"Christine F. Skibola","is_ca":false},{"name":"Paige M. Bracci","is_ca":false},{"name":"Eran Halperin","is_ca":false},{"name":"Lucía Conde","is_ca":false},{"name":"David W. Craig","is_ca":false},{"name":"Luz Agana","is_ca":false},{"name":"Kelly Iyadurai","is_ca":false},{"name":"Nikolaus Becker","is_ca":false},{"name":"Angela Brooks‐Wilson","is_ca":true},{"name":"John Curry","is_ca":false},{"name":"John J. Spinelli","is_ca":true},{"name":"Elizabeth A. Holly","is_ca":false},{"name":"Jacques Riby","is_ca":false},{"name":"Luoping Zhang","is_ca":false},{"name":"Alexandra Nieters","is_ca":false},{"name":"Martyn T. Smith","is_ca":false},{"name":"Kevin M. Brown","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01167607600136909,"gpt":0.2837860582958836,"spread":0.2721099822945145,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003567412,0.0007096617,0.0002995133,0.001411195,0.0004135544,0.0004069572,0.0004737407,0.001008346,0.006166507],"category_scores_gemma":[0.002694255,0.0002998289,0.0003655599,0.0013888,0.0004005788,0.0002194898,0.0003132489,0.0007029939,0.000624851],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001865275,"about_ca_system_score_gemma":0.000117153,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001586496,"about_ca_topic_score_gemma":0.001156626,"domain_scores_codex":[0.9996227,0.0001296075,0.00003705039,0.00007170271,0.00008227502,0.00005666064],"domain_scores_gemma":[0.9986688,0.0005094543,0.0005225752,0.00007345541,0.00007275931,0.0001529569],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007971982,0.0003214532,0.7537622,0.0002595451,0.0008067887,0.02396254,0.001074933,0.001363094,0.1675772,0.001787835,0.004014282,0.03709804],"study_design_scores_gemma":[0.0002657076,0.0004894064,0.9582795,0.00006734786,0.0004506229,0.02752966,0.0002582783,0.001217839,0.005921177,0.002093261,0.00338913,0.00003799657],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971878,0.0006687093,0.000416642,0.0002794011,0.00002255983,0.00001158696,0.0002817993,0.00003601888,0.001095592],"genre_scores_gemma":[0.9987872,0.0002159012,0.0002944939,0.00003736051,0.00005064677,0.000006594667,0.0001617815,0.00001083145,0.0004353246],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006166507,"threshold_uncertainty_score":0.02062905,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4281385697","doi":"10.1182/blood.2021015014","title":"Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital; University of Calgary","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; National Institutes of Health; Servier; BeiGene; Adaptive Biotechnologies; TG Therapeutics; Incyte; F. Hoffmann-La Roche; Amsterdam University Medical Centers; Gilead Sciences; Universiteit van Amsterdam; Leukemia and Lymphoma Society; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Amgen; Breast Cancer Research Foundation; Celgene; Pharmacyclics; Genentech; California Institute for Regenerative Medicine","keywords":"Rituximab; Medicine; Venetoclax; Bendamustine; Internal medicine; Regimen; Population; Progression-free survival; Oncology; Chemotherapy regimen; Gastroenterology; Chemotherapy; Surgery; Chronic lymphocytic leukemia; Leukemia; Lymphoma","authors":[{"name":"John F. Seymour","is_ca":false},{"name":"Thomas J. Kipps","is_ca":false},{"name":"Barbara Eichhorst","is_ca":false},{"name":"James D’Rozario","is_ca":false},{"name":"Carolyn Owen","is_ca":true},{"name":"Sarit Assouline","is_ca":true},{"name":"Nicole Lamanna","is_ca":false},{"name":"Tadeusz Robak","is_ca":false},{"name":"Javier de la Serna","is_ca":false},{"name":"Ulrich Jaeger","is_ca":false},{"name":"Guillaume Cartron","is_ca":false},{"name":"Marco Montillo","is_ca":false},{"name":"Clemens Mellink","is_ca":false},{"name":"Brenda Chyla","is_ca":false},{"name":"Anesh Panchal","is_ca":false},{"name":"Tong Lu","is_ca":false},{"name":"Jenny Wu","is_ca":false},{"name":"Yanwen Jiang","is_ca":false},{"name":"Marcus Lefebure","is_ca":false},{"name":"Michelle Boyer","is_ca":false},{"name":"Arnon P. Kater","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01165059563415755,"gpt":0.260368235767024,"spread":0.2487176401328665,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002546189,0.0002411047,0.0006783395,0.0004550753,0.0002257777,0.0006869396,0.0003514143,0.0004448398,0.0008768669],"category_scores_gemma":[0.003127485,0.0001120735,0.0007950591,0.0005059104,0.0002376724,0.0006825319,0.0004073826,0.0008647512,0.0001685733],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004761363,"about_ca_system_score_gemma":0.0002552711,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009863474,"about_ca_topic_score_gemma":0.001294597,"domain_scores_codex":[0.9992686,0.0002926311,0.00006453411,0.0001195612,0.0001252335,0.0001294089],"domain_scores_gemma":[0.9969667,0.0007045274,0.001563173,0.0002055381,0.0001759976,0.0003840982],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1000494,0.001368555,0.7408018,0.0004296196,0.001676747,0.000444631,0.000358014,0.003098695,0.003911972,0.0003241507,0.001558108,0.1459783],"study_design_scores_gemma":[0.001783888,0.01924475,0.9711154,0.0000842703,0.001402413,0.0008394849,0.00009604899,0.001373246,0.001392431,0.0004868383,0.002136688,0.00004449431],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958229,0.002588726,0.0001732045,0.00007352855,0.00001313406,0.0000188762,0.0005140313,0.00001043812,0.0007851846],"genre_scores_gemma":[0.9982671,0.000327183,0.0001007162,0.00006088773,0.00002762907,0.00001792506,0.0009580821,0.000002736249,0.0002377431],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002546189,"threshold_uncertainty_score":0.0134657,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1985094563","doi":"10.1084/jem.191.5.781","title":"A Dual Role for Src Homology 2 Domain–Containing Inositol-5-Phosphatase (Ship) in Immunity","year":2000,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; Terry Fox Research Institute; BC Cancer Agency","funders":"National Cancer Institute; Medical Research Council; Medical Research Council Canada","keywords":"Biology; B cell; Cell biology; Antigen; Receptor; Molecular biology; Immunology; Antibody; Biochemistry","authors":[{"name":"Cheryl D. Helgason","is_ca":true},{"name":"Christian P. Kalberer","is_ca":true},{"name":"Jacqueline E. Damen","is_ca":true},{"name":"Suzanne M. Chappel","is_ca":true},{"name":"Nicolas Pineault","is_ca":true},{"name":"Gerald Krystal","is_ca":true},{"name":"R. Keith Humphries","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02534752383577781,"gpt":0.3498490093042118,"spread":0.3245014854684339,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001584856,0.0003037992,0.0001463492,0.0001383328,0.0001327598,0.000330211,0.0001789123,0.000291088,0.00106287],"category_scores_gemma":[0.00007074855,0.00008624333,0.0001479843,0.00007886691,0.0003227102,0.0003879507,0.0004133226,0.0004791148,0.0002702783],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001428491,"about_ca_system_score_gemma":0.0001390912,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000723519,"about_ca_topic_score_gemma":0.0001595038,"domain_scores_codex":[0.999935,0.000009972373,0.000005166874,0.00001567041,0.00001585543,0.00001833558],"domain_scores_gemma":[0.9999446,0.000007284236,0.00001628536,0.000007155619,0.000007049272,0.00001763419],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002160738,0.00002474631,0.0008273571,0.0001392083,0.00001080312,0.0005363306,0.00003200206,0.0001197788,0.9885949,0.001979681,0.0001620317,0.007357046],"study_design_scores_gemma":[0.0001264845,0.0009502263,0.02326069,0.00003089177,0.0001196235,0.008236324,0.0001643322,0.002519064,0.9313645,0.001933674,0.03127523,0.0000190578],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9562812,0.02355139,0.01381692,0.000871132,0.0001408161,0.00004139373,0.0001566975,0.0001269317,0.00501349],"genre_scores_gemma":[0.9879434,0.005656579,0.003628324,0.0001080746,0.00008067279,0.00001721061,0.0001211924,0.00000646452,0.002438124],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00106287,"threshold_uncertainty_score":0.003555655,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2117585236","doi":"10.1371/journal.pone.0087645","title":"Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene","year":2014,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto General Hospital; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Toronto; McGill University and Génome Québec Innovation Centre","funders":"National Institute for Health and Care Research; National Institute of General Medical Sciences; Qatar National Research Fund; Japan Society for the Promotion of Science; U.S. Public Health Service; Japan Science and Technology Agency; National Institutes of Health; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Versus Arthritis; Fonds National de la Recherche Luxembourg; Canadian Institutes of Health Research; Burroughs Wellcome Fund","keywords":"Genetics; Population; Allele frequency; Pedigree chart; Allele; Candidate gene; Biology; Locus (genetics); Medicine; Gene","authors":[{"name":"Yukinori Okada","is_ca":false},{"name":"Dorothée Diogo","is_ca":false},{"name":"Jeffrey D. Greenberg","is_ca":false},{"name":"Faten Mouassess","is_ca":false},{"name":"Walid Al Achkar","is_ca":false},{"name":"Robert S. Fulton","is_ca":false},{"name":"Joshua C. Denny","is_ca":false},{"name":"Namrata Gupta","is_ca":false},{"name":"Daniel B. Mirel","is_ca":false},{"name":"Stacy Gabriel","is_ca":false},{"name":"Gang Li","is_ca":false},{"name":"Joel M. Kremer","is_ca":false},{"name":"Dimitrios A. Pappas","is_ca":false},{"name":"Robert J. Carroll","is_ca":false},{"name":"Anne E. Eyler","is_ca":false},{"name":"Gosia Trynka","is_ca":false},{"name":"Eli A. Stahl","is_ca":false},{"name":"Jing Cui","is_ca":false},{"name":"Richa Saxena","is_ca":false},{"name":"Marieke J. H. Coenen","is_ca":false},{"name":"Henk‐Jan Guchelaar","is_ca":false},{"name":"T. Huizinga","is_ca":false},{"name":"Philippe Dieudé","is_ca":false},{"name":"Xavier Mariette","is_ca":false},{"name":"Anne Barton","is_ca":false},{"name":"Helena Canhão","is_ca":false},{"name":"João Eurico Fonseca","is_ca":false},{"name":"Niek de Vries","is_ca":false},{"name":"Paul P. Tak","is_ca":false},{"name":"Larry W. Moreland","is_ca":false},{"name":"S. Louis Bridges","is_ca":false},{"name":"Corinne Miceli‐Richard","is_ca":false},{"name":"Hyon K. Choi","is_ca":false},{"name":"Pilar Galán","is_ca":false},{"name":"Mark Lathrop","is_ca":true},{"name":"Towfique Raj","is_ca":false},{"name":"Philip L. De Jager","is_ca":false},{"name":"Soumya Raychaudhuri","is_ca":false},{"name":"Jane Worthington","is_ca":false},{"name":"Leonid Padyukov","is_ca":false},{"name":"Lars Klareskog","is_ca":false},{"name":"Katherine Siminovitch","is_ca":true},{"name":"Peter K. Gregersen","is_ca":false},{"name":"Elaine R. Mardis","is_ca":false},{"name":"Thurayya Arayssi","is_ca":false},{"name":"Layla Kazkaz","is_ca":false},{"name":"Robert M. Plenge","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09977477278799306,"gpt":0.3187639287372409,"spread":0.2189891559492478,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007860995,0.0006251422,0.0008267486,0.001397797,0.0007482672,0.0007925255,0.0006014033,0.0006136526,0.002653392],"category_scores_gemma":[0.001793888,0.0004063247,0.0008083952,0.001726558,0.0003718784,0.0003004238,0.001212876,0.0009004801,0.0005661783],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002717279,"about_ca_system_score_gemma":0.0002830744,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00451495,"about_ca_topic_score_gemma":0.009943345,"domain_scores_codex":[0.9995017,0.0001126281,0.00003383426,0.000219334,0.00007457674,0.00005786072],"domain_scores_gemma":[0.999122,0.0003537389,0.0002141911,0.0001346579,0.0000625374,0.0001129892],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002351384,0.0003287277,0.5031444,0.0007622904,0.003359676,0.004141492,0.001694559,0.005616178,0.3875405,0.001125474,0.00151651,0.08841877],"study_design_scores_gemma":[0.0003203422,0.0006568189,0.9329491,0.000203409,0.002132774,0.00716073,0.0007081899,0.01819849,0.02054176,0.003461207,0.0135707,0.00009645423],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816265,0.002085611,0.01173081,0.0001381501,0.00001800881,0.00004090763,0.00324455,0.000155096,0.0009604282],"genre_scores_gemma":[0.9788302,0.0007799944,0.01242876,0.0001716094,0.00002249749,0.00006757422,0.00662706,0.0001036489,0.0009686579],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00451495,"threshold_uncertainty_score":0.008977354,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2043831614","doi":"10.1182/blood-2008-09-177329","title":"Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University Medical Centre","funders":"National Cancer Institute","keywords":"Medicine; Fludarabine; Rituximab; Waldenstrom macroglobulinemia; Internal medicine; Macroglobulinemia; Neutropenia; Gastroenterology; Surgery; Lymphoma; Chemotherapy; Cyclophosphamide; Multiple myeloma","authors":[{"name":"Steven P. Treon","is_ca":false},{"name":"Andrew R. Branagan","is_ca":false},{"name":"Leukothea Ioakimidis","is_ca":false},{"name":"Jacob D. Soumerai","is_ca":false},{"name":"Christopher J. Patterson","is_ca":false},{"name":"Barry Turnbull","is_ca":false},{"name":"Parveen Wasi","is_ca":true},{"name":"Christos Emmanouilides","is_ca":false},{"name":"Stanley R. Frankel","is_ca":false},{"name":"Andrew Lister","is_ca":false},{"name":"Pierre Morel","is_ca":false},{"name":"Jeffrey Matous","is_ca":false},{"name":"Stephanie A. Gregory","is_ca":false},{"name":"Eva Kimby","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02937707616211306,"gpt":0.3144924683044922,"spread":0.2851153921423791,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002668973,0.0003452679,0.0007920986,0.0002466929,0.0006330074,0.0007035224,0.0003590716,0.000895884,0.0005068398],"category_scores_gemma":[0.003051002,0.000173849,0.001099157,0.0002717025,0.000400273,0.0005318201,0.0005472528,0.0006768216,0.0002130295],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004294737,"about_ca_system_score_gemma":0.000306992,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000428981,"about_ca_topic_score_gemma":0.0007678684,"domain_scores_codex":[0.9990056,0.0004520802,0.000118045,0.00010821,0.0001050603,0.0002110289],"domain_scores_gemma":[0.9972137,0.0005238988,0.001068629,0.0001366927,0.0001897301,0.0008674841],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02781413,0.002596394,0.9015254,0.0002060626,0.001691706,0.002222916,0.0003639933,0.0009295548,0.005895478,0.00006908148,0.0006439059,0.05604143],"study_design_scores_gemma":[0.00274454,0.08334126,0.8998925,0.00009086124,0.001630395,0.005255455,0.0002909274,0.001001839,0.002324324,0.000173346,0.003208443,0.00004613476],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951501,0.004276433,0.00009481978,0.00009676059,0.00001881311,0.00001887821,0.00008156447,0.000004226506,0.000258274],"genre_scores_gemma":[0.998704,0.0004547744,0.00006956985,0.0001807824,0.0000604079,0.0000266683,0.0003189744,0.000002027362,0.0001828529],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002668973,"threshold_uncertainty_score":0.0141151,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1988367968","doi":"10.1182/blood-2012-02-408773","title":"A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; University Health Network; University of British Columbia; London Health Sciences Centre; Jewish General Hospital; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Obinutuzumab; Medicine; Neutropenia; Internal medicine; Maintenance therapy; Tolerability; Regimen; Rituximab; Phases of clinical research; Population; CD20; Gastroenterology; Surgery; Lymphoma; Oncology; Clinical trial; Chemotherapy; Adverse effect","authors":[{"name":"Laurie H. Sehn","is_ca":true},{"name":"Sarit Assouline","is_ca":true},{"name":"Douglas A. Stewart","is_ca":false},{"name":"Joy Mangel","is_ca":true},{"name":"Randy D. Gascoyne","is_ca":true},{"name":"Gregg Fine","is_ca":false},{"name":"Susan Frances-Lasserre","is_ca":false},{"name":"David Carlile","is_ca":false},{"name":"Michael Crump","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.009608775374167903,"gpt":0.2575599199963363,"spread":0.2479511446221684,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001438551,0.001519594,0.002392263,0.0004558737,0.0005707807,0.0007499512,0.0009200115,0.001126228,0.001723926],"category_scores_gemma":[0.001060837,0.0006754906,0.001079225,0.0003793516,0.0007707932,0.000819625,0.0003420612,0.002715471,0.0005153833],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007552152,"about_ca_system_score_gemma":0.001411328,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000786128,"about_ca_topic_score_gemma":0.001622575,"domain_scores_codex":[0.9995247,0.0002088758,0.00001966961,0.00008568045,0.00003861758,0.0001225222],"domain_scores_gemma":[0.9992068,0.0001311485,0.0001633636,0.00006252243,0.00003929857,0.0003968992],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.628311,0.1759596,0.01205221,0.0007665263,0.0009678921,0.0006061062,0.0005787854,0.003057937,0.04352934,0.0002624659,0.001924909,0.1319833],"study_design_scores_gemma":[0.1916632,0.7965205,0.007761988,0.00002210683,0.000179556,0.0001978145,0.00003364754,0.0006220294,0.001921853,0.00008616941,0.0009708927,0.00002021763],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996407,0.001327339,0.0002862426,0.0001436162,0.00007275277,0.001044207,0.0001901383,0.00003004826,0.0004986704],"genre_scores_gemma":[0.9931093,0.001311544,0.001028509,0.0004737149,0.000201544,0.001717017,0.0008413543,0.00001696273,0.001300079],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002392263,"threshold_uncertainty_score":0.007607937,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4308949853","doi":"10.1038/s41573-022-00582-5","title":"Beyond PI3Ks: targeting phosphoinositide kinases in disease","year":2022,"lang":"en","type":"review","venue":"Nature Reviews Drug Discovery","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Victoria; University of British Columbia","funders":"National Center for Advancing Translational Sciences; National Institute of General Medical Sciences; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Cancer Research Society; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Michael Smith Health Research BC; National Cancer Institute; National Science Foundation","keywords":"Phosphoinositide 3-kinase; Kinase; Disease; Medicine; Biology; Cancer research; Signal transduction; Cell biology; PI3K/AKT/mTOR pathway; Internal medicine","authors":[{"name":"John E. Burke","is_ca":true},{"name":"Joanna Triscott","is_ca":false},{"name":"Brooke M. Emerling","is_ca":false},{"name":"Gerald Hammond","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03358830935975977,"gpt":0.3736598770361418,"spread":0.3400715676763821,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008459727,0.001247368,0.001867779,0.002207549,0.000278767,0.001436905,0.001116119,0.001681939,0.006784307],"category_scores_gemma":[0.0008493209,0.0003416963,0.0007603376,0.001977739,0.0006728464,0.00191927,0.001028255,0.003374777,0.004244069],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008684811,"about_ca_system_score_gemma":0.00112049,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009949773,"about_ca_topic_score_gemma":0.00316058,"domain_scores_codex":[0.9997861,0.0000338799,0.00002176945,0.00003234458,0.00008986714,0.00003605839],"domain_scores_gemma":[0.9996603,0.0001585864,0.00003966178,0.000009791807,0.00007970311,0.00005194216],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002160101,0.00008211676,0.0000943187,0.01272621,0.0001375575,0.0001659821,0.00003491117,0.0004293703,0.002326988,0.003466477,0.07945465,0.9008654],"study_design_scores_gemma":[0.00009801607,0.000148826,0.0003388838,0.002325058,0.0001730896,0.0004733227,0.00002594177,0.0001323685,0.0003296108,0.002210204,0.9937256,0.00001908096],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00007391968,0.9977146,0.000168567,0.0005180218,0.0004640996,0.000006077235,0.00003131805,0.00001660319,0.001006792],"genre_scores_gemma":[0.0005261424,0.9974717,0.0001990558,0.0005907983,0.0003259426,0.000008295217,0.00004904132,0.000002386394,0.0008266554],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.006784307,"threshold_uncertainty_score":0.02269584,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2290262197","doi":"10.1126/scitranslmed.aad7666","title":"A dominant gain-of-function mutation in universal tyrosine kinase <i>SRC</i> causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies","year":2016,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Infection and Immunity","funders":"National Heart, Lung, and Blood Institute; NIHR Cambridge Biomedical Research Centre; NIHR BioResource; Vlaamse regering; Fonds Wetenschappelijk Onderzoek; Onderzoeksraad, KU Leuven; Imperial College London; British Heart Foundation; KU Leuven; National Institute for Health and Care Research; Medical Research Council; British Society for Haematology; NHS Blood and Transplant","keywords":"Myelofibrosis; Gain of function; Medicine; Proto-oncogene tyrosine-protein kinase Src; Tyrosine kinase; Mutation; Function (biology); Platelet; Cancer research; Internal medicine; Bone marrow; Biology; Receptor; Genetics; Gene","authors":[{"name":"Ernest Turro","is_ca":false},{"name":"Daniel Greene","is_ca":false},{"name":"Anouck Wijgaerts","is_ca":false},{"name":"Chantal Thys","is_ca":false},{"name":"Claire Lentaigne","is_ca":false},{"name":"Tadbir K. Bariana","is_ca":false},{"name":"Sarah K. Westbury","is_ca":false},{"name":"Anne M. Kelly","is_ca":false},{"name":"Dominik Selleslag","is_ca":false},{"name":"Jonathan Stephens","is_ca":false},{"name":"Sofia Papadia","is_ca":false},{"name":"Ilenia Simeoni","is_ca":false},{"name":"Christopher J. Penkett","is_ca":false},{"name":"Sofie Ashford","is_ca":false},{"name":"Antony Attwood","is_ca":false},{"name":"Steve Austin","is_ca":false},{"name":"Tamam Bakchoul","is_ca":false},{"name":"Peter Collins","is_ca":true},{"name":"Sri V. V. Deevi","is_ca":false},{"name":"Rémi Favier","is_ca":false},{"name":"Myrto Kostadima","is_ca":false},{"name":"Michele P. Lambert","is_ca":false},{"name":"Mary Mathias","is_ca":false},{"name":"Carolyn M. Millar","is_ca":false},{"name":"Kathelijne Peerlinck","is_ca":false},{"name":"David J. Perry","is_ca":false},{"name":"Sol Schulman","is_ca":false},{"name":"Deborah Whitehorn","is_ca":false},{"name":"Christine Wittevrongel","is_ca":false},{"name":"Marc De Maeyer","is_ca":false},{"name":"Augusto Rendon","is_ca":false},{"name":"Keith Gomez","is_ca":false},{"name":"Wendy N. Erber","is_ca":false},{"name":"Andrew Mumford","is_ca":false},{"name":"Paquita Nurden","is_ca":false},{"name":"Kathleen Stirrups","is_ca":false},{"name":"John R. Bradley","is_ca":false},{"name":"F. Lucy Raymond","is_ca":false},{"name":"Michael Laffan","is_ca":false},{"name":"Chris Van Geet","is_ca":false},{"name":"Sylvia Richardson","is_ca":false},{"name":"Kathleen Freson","is_ca":false},{"name":"Willem H. Ouwehand","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02917084554683468,"gpt":0.3120914435771577,"spread":0.282920598030323,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001166316,0.0005978586,0.0002203274,0.0004130571,0.0001659456,0.0001639075,0.0001735509,0.0003029512,0.001855402],"category_scores_gemma":[0.0001682754,0.0001495657,0.0002529185,0.0002455972,0.0003019065,0.00007219428,0.0002212583,0.0002812165,0.0003782192],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002069771,"about_ca_system_score_gemma":0.0001423071,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003436522,"about_ca_topic_score_gemma":0.0006626946,"domain_scores_codex":[0.9998894,0.00001420321,0.00001427989,0.00002911253,0.0000278688,0.00002506132],"domain_scores_gemma":[0.9998748,0.00003042578,0.00003939988,0.00001105945,0.000007346507,0.00003679259],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.0002219205,0.00007609915,0.01537488,0.00005800957,0.00005136996,0.0100653,0.00004228274,0.0001758974,0.9638054,0.0004350594,0.0005802083,0.009113563],"study_design_scores_gemma":[0.0001620841,0.001605136,0.1890751,0.00004528942,0.0002605558,0.2355141,0.0001271639,0.005031797,0.5554686,0.0004677246,0.01220734,0.00003515055],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994803,0.0003578103,0.001923196,0.00009085345,0.00001496009,0.00002725024,0.0004583163,0.0001461043,0.002178604],"genre_scores_gemma":[0.9972667,0.0002224874,0.001294128,0.00004986182,0.000009844403,0.000007808975,0.0004246488,0.00002344712,0.0007010262],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001855402,"threshold_uncertainty_score":0.00620693,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2129783860","doi":"10.1182/blood-2008-04-150854","title":"Thalidomide and rituximab in Waldenstrom macroglobulinemia","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Thalidomide; Medicine; Rituximab; Internal medicine; Gastroenterology; Waldenstrom macroglobulinemia; Macroglobulinemia; Population; Adverse effect; Immunology; Surgery; Multiple myeloma; Lymphoma","authors":[{"name":"Steven P. Treon","is_ca":false},{"name":"Jacob D. Soumerai","is_ca":false},{"name":"Andrew R. Branagan","is_ca":false},{"name":"Zachary R. Hunter","is_ca":false},{"name":"Christopher J. Patterson","is_ca":false},{"name":"Leukothea Ioakimidis","is_ca":false},{"name":"Frederick Briccetti","is_ca":false},{"name":"Mark Pasmantier","is_ca":false},{"name":"Harvey Zimbler","is_ca":false},{"name":"Robert B. Cooper","is_ca":false},{"name":"Maria Moore","is_ca":false},{"name":"John M. Hill","is_ca":false},{"name":"Alan E. Rauch","is_ca":false},{"name":"Lawrence Garbo","is_ca":false},{"name":"Luis Chu","is_ca":false},{"name":"Cynthia C. Chua","is_ca":false},{"name":"Stephen H. Nantel","is_ca":true},{"name":"David Lovett","is_ca":false},{"name":"Hans Boedeker","is_ca":false},{"name":"Henry Sonneborn","is_ca":false},{"name":"John R. Howard","is_ca":false},{"name":"P. Musto","is_ca":false},{"name":"Bryan Ciccarelli","is_ca":false},{"name":"Evdoxia Hatjiharissi","is_ca":false},{"name":"Kenneth C. Anderson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0194764630623255,"gpt":0.2690334252907942,"spread":0.2495569622284687,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001513958,0.0003748051,0.0009406355,0.0002178016,0.0001817633,0.0003872007,0.0003863975,0.0005136178,0.0006278193],"category_scores_gemma":[0.0007509291,0.000256396,0.0004344982,0.0002337495,0.0003672554,0.0004394825,0.000238278,0.0007089383,0.0001448531],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003708797,"about_ca_system_score_gemma":0.0005353206,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003830403,"about_ca_topic_score_gemma":0.001289244,"domain_scores_codex":[0.9994472,0.0003654351,0.00002918966,0.00003481359,0.00004943008,0.00007391349],"domain_scores_gemma":[0.9996817,0.0001182186,0.00005483427,0.00001400358,0.0000126543,0.0001186283],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.2753235,0.03318834,0.05677698,0.001266097,0.001397955,0.002325438,0.0008606724,0.003478036,0.1377356,0.0009368241,0.002644835,0.4840658],"study_design_scores_gemma":[0.1688566,0.6968213,0.1048238,0.0001121678,0.0007746941,0.002874283,0.0002044968,0.003079738,0.01429925,0.0003446071,0.007762675,0.00004644105],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957486,0.003455164,0.0001075656,0.00008389001,0.00001894131,0.00008681652,0.00001564677,0.000008662517,0.0004746456],"genre_scores_gemma":[0.9978722,0.001189306,0.0003330802,0.0001431309,0.00005493693,0.000119034,0.00008964082,0.000002690754,0.0001958826],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001513958,"threshold_uncertainty_score":0.008006692,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2129141528","doi":"10.1016/j.ccell.2015.02.003","title":"Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia","year":2015,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"National Cancer Institute; Cancer Research UK; Wellcome Trust; Howard Hughes Medical Institute","keywords":"breakpoint cluster region; Cancer research; Biology; BCL6; Tyrosine kinase; Signal transduction; Leukemia; Kinase; Receptor; Cell biology; Immunology; B cell; Genetics; Antibody","authors":[{"name":"Huimin Geng","is_ca":false},{"name":"Christian Hurtz","is_ca":false},{"name":"Kyle Lenz","is_ca":false},{"name":"Zhengshan Chen","is_ca":false},{"name":"Dirk Baumjohann","is_ca":false},{"name":"Sarah K. Thompson","is_ca":false},{"name":"Natalya A. Goloviznina","is_ca":false},{"name":"Wei‐Yi Chen","is_ca":false},{"name":"Jianya Huan","is_ca":false},{"name":"Dorian LaTocha","is_ca":false},{"name":"Erica Ballabio","is_ca":false},{"name":"Gang Xiao","is_ca":false},{"name":"Jae Woong Lee","is_ca":false},{"name":"Anne Deucher","is_ca":false},{"name":"Zhongxia Qi","is_ca":false},{"name":"Eugene Park","is_ca":false},{"name":"Chuanxin Huang","is_ca":false},{"name":"Rahul Nahar","is_ca":false},{"name":"Soo-Mi Kweon","is_ca":false},{"name":"Seyedmehdi Shojaee","is_ca":false},{"name":"Lai N. Chan","is_ca":false},{"name":"Jingwei Yu","is_ca":false},{"name":"Steven M. Kornblau","is_ca":false},{"name":"Janet J. Bijl","is_ca":true},{"name":"B. Hilda Ye","is_ca":false},{"name":"K. Mark Ansel","is_ca":false},{"name":"Elisabeth Paietta","is_ca":false},{"name":"Ari Melnick","is_ca":false},{"name":"Stephen P. Hunger","is_ca":false},{"name":"Peter Kurre","is_ca":false},{"name":"Jeffrey Tyner","is_ca":false},{"name":"Mignon L. Loh","is_ca":false},{"name":"Robert G. Roeder","is_ca":false},{"name":"Brian Druker","is_ca":false},{"name":"Jan A. Burger","is_ca":false},{"name":"Thomas A. Milne","is_ca":false},{"name":"Bill H. Chang","is_ca":false},{"name":"Markus Müschen","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02639569403894095,"gpt":0.2885069859949592,"spread":0.2621112919560182,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001780547,0.0001895205,0.0002841317,0.0005052641,0.0003831681,0.001418381,0.0005121222,0.0003323894,0.00237586],"category_scores_gemma":[0.000319491,0.0001679662,0.0002187374,0.0003795284,0.0003984766,0.0004006848,0.0005625715,0.000796111,0.0007413561],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006017869,"about_ca_system_score_gemma":0.0003081582,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00114891,"about_ca_topic_score_gemma":0.001572272,"domain_scores_codex":[0.9996914,0.00004212762,0.00002042113,0.00004976811,0.0000907556,0.0001055669],"domain_scores_gemma":[0.9997264,0.00003763854,0.00007112938,0.00006808976,0.00003585154,0.00006090566],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0008827869,0.0001842738,0.03045933,0.00004145572,0.00001774605,0.000519074,0.000261339,0.0002313701,0.9504926,0.005081702,0.0005035961,0.01132459],"study_design_scores_gemma":[0.0002634972,0.001523524,0.3408087,0.00003830191,0.0001160936,0.02606706,0.002497492,0.007313378,0.5825965,0.004186545,0.03453552,0.00005339687],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960272,0.0004738382,0.0009694798,0.00008348763,0.00001187105,0.00001833471,0.0001986341,0.00006403196,0.002153025],"genre_scores_gemma":[0.997581,0.0002110461,0.000437246,0.00005868073,0.000009649765,0.00001016437,0.0003982442,0.00001678653,0.001277051],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00237586,"threshold_uncertainty_score":0.007948101,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2158196950","doi":"10.3324/haematol.13151","title":"Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia","year":2008,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Lymphocytosis; Dasatinib; Natural killer cell; Lymphocyte; Immunology; CD16; CD3; Biology; Medicine; Cytotoxicity; Myeloid leukemia; CD8; Imatinib; Immune system","authors":[{"name":"Dong H. Kim","is_ca":true},{"name":"Suzanne Kamel‐Reid","is_ca":true},{"name":"Hong Chang","is_ca":true},{"name":"Robert Sutherland","is_ca":true},{"name":"Chang Wook Jung","is_ca":false},{"name":"H.-J. Kim","is_ca":false},{"name":"J.-J. Lee","is_ca":false},{"name":"Jeffrey H. Lipton","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03405269464848501,"gpt":0.2943099288139732,"spread":0.2602572341654882,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001630337,0.0003166116,0.0004035981,0.0003443762,0.0003045906,0.0002960313,0.0001547252,0.0003610861,0.0009029545],"category_scores_gemma":[0.001205591,0.0001339089,0.0002065075,0.0003417695,0.0004477032,0.0002826796,0.0002601219,0.0003780446,0.0002110955],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002283255,"about_ca_system_score_gemma":0.0002415833,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003468271,"about_ca_topic_score_gemma":0.0005531264,"domain_scores_codex":[0.9997368,0.00006345526,0.00003590988,0.00004478392,0.00004299141,0.00007604949],"domain_scores_gemma":[0.999373,0.0002072616,0.0002172563,0.00005496831,0.00003446298,0.000113094],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"case_report","study_design_scores_codex":[0.002416209,0.0002418812,0.6575785,0.0001961929,0.0000950851,0.2381774,0.000484606,0.0006560559,0.05249575,0.0002805563,0.0007187144,0.04665907],"study_design_scores_gemma":[0.0002103816,0.001809435,0.2896168,0.00001877668,0.0001146409,0.6888719,0.00025789,0.001350701,0.01520464,0.0002390028,0.002283799,0.00002204019],"study_design_candidate":"case_report","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980573,0.0003842849,0.0004517023,0.0000523036,0.000004923607,0.00001955507,0.00002219965,0.00001536675,0.0009923909],"genre_scores_gemma":[0.9996765,0.00009139724,0.00009262032,0.00002100573,0.00001021813,0.000003197997,0.0000276147,0.000001691599,0.00007580625],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009029545,"threshold_uncertainty_score":0.003020644,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2787624638","doi":"10.1182/blood-2017-06-792267","title":"Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia","year":2018,"lang":"en","type":"letter","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Chronic lymphocytic leukemia; Tumor microenvironment; Stromal cell; Cancer research; Immune checkpoint; Immune system; Blockade; Ibrutinib; Leukemia; Medicine; Immunology; Biology; Immunotherapy; Receptor; Internal medicine","authors":[{"name":"Marina Wierz","is_ca":false},{"name":"Sandrine Pierson","is_ca":false},{"name":"Léa Guyonnet","is_ca":true},{"name":"Elodie Viry","is_ca":false},{"name":"Audrey Lequeux","is_ca":false},{"name":"Anaïs Oudin","is_ca":false},{"name":"Simone P. Niclou","is_ca":false},{"name":"Markus Ollert","is_ca":true},{"name":"Guy Berchem","is_ca":false},{"name":"Bassam Janji","is_ca":false},{"name":"Coralie L. Guérin","is_ca":true},{"name":"Jérôme Paggetti","is_ca":false},{"name":"Etienne Moussay","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02813684716392201,"gpt":0.2685611499825817,"spread":0.2404243028186597,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007546656,0.000217397,0.0003496367,0.0002023996,0.0007037089,0.0007488682,0.0002807388,0.004845366,0.003266376],"category_scores_gemma":[0.003120109,0.0001183264,0.0002114958,0.00009979091,0.0006046708,0.0004481227,0.0002305237,0.00341252,0.001528573],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009818325,"about_ca_system_score_gemma":0.0004891786,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003626585,"about_ca_topic_score_gemma":0.0008460347,"domain_scores_codex":[0.9995389,0.0001876177,0.00004067095,0.00003636761,0.0001301504,0.00006638005],"domain_scores_gemma":[0.9988003,0.0006760595,0.0001130186,0.00006820845,0.0002011748,0.000141272],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001408409,0.0003652385,0.005158846,0.0002219343,0.00003603135,0.03296351,0.0002813911,0.0004204392,0.01803613,0.01583941,0.8109422,0.1143265],"study_design_scores_gemma":[0.0004227954,0.0007343919,0.002303739,0.0001564394,0.00004943632,0.02185611,0.0002837028,0.001948639,0.01165469,0.009684781,0.9508731,0.00003208892],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.05029719,0.006331529,0.002275543,0.8744285,0.02506847,0.0001060318,0.0001930724,0.0003409206,0.04095873],"genre_scores_gemma":[0.4360436,0.01023898,0.005410117,0.4220612,0.0370478,0.000189685,0.0002820964,0.0001031547,0.08862333],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.004845366,"threshold_uncertainty_score":0.01092708,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}